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ACE         angiotensin-converting enzyme
Ang I angiotensin I
Ang II        angiotensin II
AP-1        activator protein-1
AT1 angiotensin II receptor type 1
AT2 angiotensin II receptor type 2
BSA        Bovine Serum Albumin
CCA       common carotid artery
CE       converting enzyme
CSF      cerebrospinal fluid
CAMP adenosine 3’, 5’-cyclic monophosphate
CBF       cerebral blood flow
ECA       external carotid artery
EDTA ethylenediaminetetraacetic acid
ICA       internal carotid artery
IL-1β      interleukin-1β
IL-6       interleukin-6
IP-3         inositol 1,4,5-triphosphate
ITFs        inducible transcription factors
LDF      laser-Doppler flowmetry
MAP      mean arterial blood pressure
MCA      middle cerebral artery
MCAO       middle cerebral artery occlusion
MCP-1    monocyte chemoattractant protein-1
NF-kB     nuclear factor kB
NGS     normal goat serum
NMDA N-methyl-D-aspartate
PARP        cleavage of poly (ADP-ribose) polymerase
PB         Phosphate Buffer
PBS        Phosphate Buffered Saline
PRA      plasma renin activity
VI
RAS         renin-angiotensin system
rCBF         regional cerebral blood flow
RT     room temperature
SAH     subarachnoid hemorrhage
SBP        systolic blood pressure
SHR spontaneously hypertensive rat
SHRSP       stoke-prone spontaneously hypertensive rat
TUNEL                      Terminal deoxynucleotidyl transferase-mediated dUTP nick-end
labeling
VSMC     vascular smooth muscle cells
11 Introduction
1.1 Stroke and animal models of stroke
Stroke is a cardiovascular disease affecting the blood vessels that supply oxygen and nutrients
to the brain. A stroke occurs when a blood vessel within the brain or leading to the brain
ruptures or is clogged e.g. by a thrombus. Four types of stroke can be distinguished. The first
two, cerebral thrombosis and cerebral embolism, are caused by blood vessel occlusion and
account for almost 80 % of all stokes. The other two types, subarachnoid hemorrhage and
intracerebral hemorrhage, are caused by bleeding or hemorrhage, often as a result of an
aneurysm in the brain or a head injury, and are classified as hemorrhagic strokes.
Stroke is the third most common cause of death in most western populations after coronary-
heart disease and cancer. It is also an important cause of serious, long-term disability in
patients who survive and experience the physical and mental consequences of insult for many
years thereafter.
The development of reliable animal models of stroke based on similarities with syndromes of
human cerebrovascular disease would allow the study of the pathophysiology of this disease
as well as the efficacy of various treatment modalities. In the present studies, we used two
different animal models of stroke namely the stroke-prone spontaneously hypertensive rat
(SHRSP) and a model of focal cerebral ischemia induced by the temporal occlusion of the
middle cerebral artery.
1.1.1 Stroke-prone spontaneously hypertensive rats
In 1963, spontaneously hypertensive rats (SHR) were isolated from a Wistar-Kyoto rat colony
by Okamoto and Aoki (Okamoto and Aoki, 1963). Later, the SHR colony was further
separated by Okamoto and his colleagues into several sublines (Okamoto et al., 1972), some
of which had a tendency to develop cerebrovascular lesions (cerebral hemorrhage and/or
infarction) and are named stroke–prone SHR. The SHRSP is a genetic model of severe
hypertension in which the incidence of cerebral disorders and spontaneous stroke is very high
(Okamoto et al., 1974). Because of the similarity between the cerebrovascular lesions
observed in SHRSP and those observed in humans, SHRSP have long been used for the
investigation of preventive therapies for stroke.
It is well known that high blood pressure is one of the causative factors of stroke in humans
and that abnormally high salt intake results in an elevation of the blood pressure. In SHRSP
increased salt intake accelerated the development of hypertension and the occurrence of
2stroke. When maintained on a 1% NaCl drinking solution and supplemented with a special so-
called “japan diet”, these rats rapidly develop malignant hypertension and stroke (Nagaoka et
al., 1976 and Stier et al., 1988).
1.1.2 Intraluminal thread model of focal cerebral ischemia
Animal models of focal cerebral ischemia are generally intended to replicate features of
human focal ischemic stroke produced by occlusion of a single cerebral artery. Thus, the vast
majority of animal models of focal cerebral ischemia employ middle cerebral artery occlusion
(MCAO). This is surgically feasible in primate, cats, and rodents, especially rats. The most
frequently used procedures to achieve occlusion are coagulation of the MCA through a
temporal craniectomy (Tamura et al., 1981; Coyle, 1982; Bederson et al., 1986) and
intraluminal thread occlusion without craniectomy via a cervical carotid approach (Koizumi et
al., 1986; Longa et al., 1989; Nagasawa and Kogure, 1989). The intraluminal occlusion
method  has become an increasingly popular tool for studying the pathophysiology and
treatment of stroke since its original description (Koizumi et al., 1986). The greatest
advantage of this model is the ease with which recirculation can be commenced simply by
pulling out the thread and re-exposing the origin of the MCA.
Regardless of the species or technique of MCA occlusion, the resulting ischemia exhibits
several important features germane to its neuropathology: a gradient of cerebral blood flow
(CBF) decrement which is lowest (typically 10-20% of control, or below) in the ischemic
core, a zone destined to develop infarction, and somewhat higher (20-40% of control) in the
surrounding penumbral zone, whose fate depends upon multiple factors. The final stage of
infarct development in focal cerebral ischemia is pan-necrosis, in which the neuronal death is
accompanied by glial and vascular cell death and loss of cellular elements (Lipton, 1999).
Animal models of focal cerebral ischemia have provided some insights into the dynamic
events involved in ischemic brain injury, and were widely used in preclinical trials. It is thus
essential to strive for lesion reproducibility, physiological controls, and rigorous assessment
of outcome by means of quantitative histopathology and secondarily by behavioral outcome
measures.
1.2 Cell death and focal cerebral ischemia
In recent years it became clear that hypoxic neurons die by two different modes: necrosis and
apoptosis (Okamoto et al., 1993; Ferrer et al., 1994). Apoptosis is an active process of cell
destruction characterized by cell shrinkage and chromatin aggregation followed by
3fragmentation, while the integrity of the cell membrane and mitochondria is still preserved.
Apoptotic cell death is energy dependent and not associated with inflammation and damage to
the neighboring tissue (Wyllie et al., 1980; Savill et al., 1993; Cohen, 1993). Necrosis is
instead characterized by passive cell swelling, intense mitochondrial damage and membrane
dysfunction. Necrosis usually causes an inflammatory response and injury to the surrounding
tissue (Choi, 1992).
Linnik et al. (1993) were the first to implicate apoptosis in focal brain ischemia. By
application of the protein synthesis inhibitor cycloheximide, they were able to reduce the size
of focal cerebral infarction by 70 %, which indicated that neuronal loss induced by ischemia
was dependent on de novo protein synthesis. Moreover, DNA fragmentation was shown in
extracts of ischemic brains indicating programmed cell death (Linnik et al., 1993, Tominaga
et al., 1993). These initial findings were extended by several groups (Manev et al., 1994; Li et
al., 1995a,b; Braun et al., 1996; Charriaut-Marlange et al., 1996 ). Li et al. (1995a,b)
identified apoptotic cells, mostly neurons, by electron microscopy in the inner boundary zone
of infarction of rats subjected to transient (2 h) focal ischemia. Apoptotic neurons increased in
number as early as 0.5 h, peaked at 24-48 h, and persisted for 4 weeks after the onset of
reperfusion. The presence of apoptotic neurons several days after ischemia suggests that cell
death after ischemia is a dynamic process and not simply caused by the initial ischemic insult.
In focal ischemia, the central lesion or core is conventionally considered necrotic (Garcia et
al., 1995a,b; Lipton, 1999), whereas the bordering area, or penumbra, recruits apoptotic
mechanisms (Linnik et al., 1993; Li et al., 1995a,b; Charriaut-Marlangue et al., 1996).
However, a large body of evidence has been accumulated, which suggests that the both
mechanisms may just represent extremes of a potentially continuous spectrum of possibilities
for a cell population to die. In tissue, apoptosis and necrosis may either co-exist or be a
sequential phenomena. The mode of cell death may be influenced by the intensity or exposure
time toward insults (Bonfoco et al., 1995; Dybpukt et al., 1995).
DNA fragmentation in the brain after focal ischemia can be detected by Terminal
deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) (Chen et al., 1997).
This is not an unambiguous identification of apoptosis because it labels both nucleosomal and
non-nucleosomal fragments (Portera-Cailliau et al., 1995). The latter are formed during
necrotic cell death.
Caspases are implicated in the control of apoptosis (Li and Yuan, 1999; Hengartner, 2000).
Given the number and diversity of caspase targets, most, if not all, of the morphological
features described for apoptosis are caspase-dependent. Caspases do not appear to be
4associated with necrotic death (Armstrong et al., 1997; Gottron et al., 1997). They participate
in cascades that include initiator and effector caspases (Friedlander et al., 1997; Fink et al.,
1998), which are both activated by ischemia (Schielke et al., 1998; Plesnila and Moskowitz,
2000). Caspase-3 is one of the key executioners of apoptosis (Cohen, 1997).
The penumbra area has been considered a therapeutic target in focal cerebral ischemia
(Ginsberg and Pulsinelli, 1994; Hossmann, 1994).  In the present study, we examined the
effect of different treatment regimens on activated caspase-3 immunoreactivity and
subsequent DNA fragmentation on the cortical penumbral area of rats with transient focal
ischemia following 2 days of reperfusion.
1.3 Microglial responses and focal cerebral ischemia
Microglia are a class of mononuclear phagocytes intrinsic to the CNS. These cells are the
principal immune effector elements of the brain and are associated with diverse clinical
problems including cerebrovascular disease (Giulian, 1992). Four forms of microglia can be
defined on the basis of developmental and pathophysiological studies. They include (1) the
amoeboid microglia, found predominantly in the white matter perinatally, (2) the ramified
microglia, found in the gray and white matter postnatally, (3) the activated microglia, found in
areas of secondary reaction due to nerve transection and CNS inflammation, and (4) the
reactive (phagocytic) microglia, found in areas of trauma, ischemic injury, or neuronal
degeneration (Hickey et al., 1992; Jordan and Thomas, 1988; Perry and Gordon, 1988; Streit
et al., 1988). Virtually all microglia of the mature CNS are found as quiescent, ramified cells
with no recognized function. During CNS injury, ramified microglia retract processes,
become more amoeboid-like, and transform into the activated or reactive microglia (del Rio-
Hortega, 1932).
In transient (2 h) MCAO, Zhang et al. (1997) described the temporal profile of the microglia
response. Round and amoeboid cells became predominant in the ischemic core lesion and
were mingled with highly ramified microglia in the boundary zone at 22 h of reperfusion. A
high number of ramified microglia was found in an adjacent area containing morphologically
intact neurons. Round and amoeboid cells were localized to the inner boundary of the
ischemic lesion surrounding the infarct zone at 46 h of reperfusion. From 70-166 h of
reperfusion round and amoeboid cells were present throughout the entire ischemic lesion in
the infarct zone. Similar results were reported by Kato et al. (1996) and by Lehrmann et al.
(1997). It remains unclear from these studies what proportion of phagocytes was microglia-
derived or recruited from the circulation. Since microglia and macrophages not only share
5heritage (Hickey et al., 1992), but also surface and endocellular markers (Flaris et al., 1993),
they become virtually indistinguishable under pathological conditions (Stoll et al., 1989;
Perry et al., 1993; George and Griffin, 1994).
There is some evidence that delayed neuronal and functional losses after ischemic injury are
the results of neurotoxic inflammatory cells (Giulian 1997). First, neuronal poisons, including
Ntox, can be only detected in tissues heavily infiltrated with reactive microglia or
macrophages. The levels of neurotoxic activity found in CNS injured by ischemia correlate
with the number of mononuclear phagocytes at the lesion sites. Importantly, no toxic activity
was detected in neighboring non-inflamed tissues. Second, drugs that reduce inflammatory
cell numbers also reduce the amount of Ntox released by damaged tissue. Third, active
mononuclear phagocytes appear at a time of a delayed loss of neurons and deterioration in
neurological function. Fourth, suppression of CNS inflammation improves both motor neuron
survival and preserves motor functions. And fifth, isolation of specific cell populations
confirmed that reactive mononuclear phagocytes are the principal source of neuron-killing
factors in damaged CNS.
The surrounding penumbra, appears to be a suitable target for immunosuppressive therapies
during the acute phase of ischemic injury. In the present study, we measured the density of
activated microglia or macrophages in the cortical penumbral area of rats with transient focal
ischemia following 2 days reperfusion, in order to evaluate the effects of different treatment
regimens on inflammation after brain ischemia.
1.4 The renin-angiotensin system and stroke
The renin-angiotensin system (RAS) is a major physiological regulator of body fluid volume,
electrolyte balance and blood pressure (Goodfriend et al., 1996; Griendling et al., 1996;
Matsukawa and Ichikawa, 1997; Ardaillou, 1999). Angiotensin II (Ang II) is a potent
vasoconstrictor hormone and is produced via the renin-angiotensin enzymatic cascade. Renin
converts angiotensinogen into the decapeptide Ang I and angiotensin-converting enzyme
(ACE) cleaves Ang I to form the active octapeptide Ang II (Ellis and Patterson, 1996; Edling
et al., 1995). The major actions of Ang II are mediated by two subtypes of G-protein-coupled
angiotensin receptors, the AT1- and AT2-receptors. Most of the classical actions of Ang II on
fluid and blood pressure homeostasis are mediated by AT1-receptors (de Gasparo et al., 2000).
The renin-angiotensin system has been implicated in the development of end-organ damage,
including strokes, in clinical and experimental situations. ACE inhibitor and Ang II AT1-
receptor antagonists have been shown to prevent the occurrence of stroke and mortality in
6SHRSP (Stier et al., 1989; Stier et al., 1991; Vacher et al., 1993; Richer et al., 1994; Camargo
et al., 1991; Fornes et al., 1993). Many experimental studies showed that both ACE inhibitors
and AT1 antagonists produced an anti-stroke effect independent of a change in blood pressure.
It has been suggested that such treatment may protect against vascular damage produced by
the elevations in plasma Ang II. A reduction in neutrophil chemoattraction to vascular
endothelium, decreased vascular smooth muscle hypertrophy and hyperplasia, decreased
vascular permeability, lowered plasma aldosterone levels, and a reduction in the incidence of
cerebrovascular fibrinoid necrosis have all been suggested as possible beneficial mechanisms
that could act to retard stroke development in response to the inhibition of the effects of Ang
II through ACE inhibitor or AT1 receptor antagonist treatment (Camargo et al., 1991; Stier et
al., 1991; Stier et al., 1989; Camargo et al., 1993; Inada et al., 1995; Lee et al., 1994; Stier et
al., 1993; MacLeod et al., 1997). However, not all of the effects of ACE inhibition can be
explained by the decrease in Ang II generation. Some of them, especially with respect to
organ protection, have also been attributed to bradykinin potentiation (Gohlke et al., 1996).
Ischemic stroke can be caused by a number of monogenic disorders, and the ACE gene is
probably the most extensively investigated candidate gene in ischemic stroke (Hassan and
Markus, 2000). ACE gene deletion polymorphism can result in a high serum level of ACE,
which was shown to increase the risk and severity of the ischemic lesions (Catto et al., 1996;
Doi et al., 1997). In animal models of  cerebral ischemia ACE inhibitors or AT1 receptor
antagonists improved the neurological outcome and reduced the infarct volume (Werner et al.,
1991; Dai et al., 1999; Ravati et al., 1999; Nishimura et al., 2000). Recently Walther et al.
(2002) demonstrated a direct correlation between brain Ang II and the severity of ischemic
injury in transgenic mice after focal cerebral ischemia. Angiotensinogen-overexpressing mice
had an enlarged infarct size and a much smaller penumbra area, and AT1 receptor knockout
mice had a smaller lesion size and a much larger penumbra area compared with their wild-
type litter-mates, after 1 or 24 h of permanent MCAO. Ischemic stroke results from a transient
or permanent reduction or interruption of cerebral blood flow, and the autoregulation of
cerebral blood flow is impaired during brain ischemia. The neuroprotective effects of ACE
inhibitors and AT1 receptor antagonists, or transgene-induced suppression of AT1 receptor,
may partly be related to the normalization of cerebrovascular autoregulation (Culman et al.,
2001; Walther et al., 2002). ACE inhibitors and AT1 receptor antagonists were shown to shift
the upper and lower limits of cerebral blood flow autoregulation to lower blood pressure
levels and result in decreased neuronal injury (Paulson et al., 1988;  Vraamark et al., 1995;
Nishimura et al., 2000; Saavedra et al., 2001). Further mechanisms are involved in the
7beneficial effect of AT1 receptor antagonists in brain ischemia. Long-term blockade of central
AT1 receptors has been shown to reduce the expression of c-Fos and c-Jun in response to
cerebral ischemia. Activation of ITFs (inducible transcription factors) after hypoxia-ischemia
represents one of the links between the extracellular signals and the initiation of intracellular
genomic metabolic events that are associated with regeneration and survival or lead to a
selective delayed neuronal death. Focal cerebral ischemia has been shown to induce the
expression of gene products of the c-Fos and c-Jun families in the nervous system. c-Jun in
particular is believed to initiate degeneration via de novo protein synthesis of apoptotic
effectors (Dai et al., 1999). The involvement of AT1 stimulation in apoptosis caused by Ang II
has been shown in myocytes (Leri et al., 1998) and endothelial cells in vitro (Li et al., 1999)
and in rat blood vessels in vivo (Diep et al., 1999). Some ACE inhibitors attenuated
cardiomyocyte apoptosis in SHR (Diez et al., 1997). These data suggested that ACE inhibitors
and AT1 receptor antagonists could have a beneficial influence on cellular apoptosis which is
thought to play a role in the pathology of several neurodegenerative diseases such as
amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s and Alzheimer’s disease as well
as stroke (Bredesen, 1995).
In contrast, several findings indicate a benefit from Ang II in brain ischemia. Infusion of Ang
II or AT2 receptor stimulation has been shown to decrease the mortality rate in gerbils with
unilateral carotid ligation (Fernandez et al., 1986; Fernandez et al., 1994). Moreover, the ACE
inhibitor, enalaprilat, and the non-selective Ang II receptor antagonist, saralasin, were shown
to increase the mortality in the same gerbil model of brain ischemia (Kaliszewski et al., 1988).
The promotion of angiogenesis and recruitment of pre-existing collateral circulation by Ang II
in case of acute ischemia have been suggested as a possible mechanism of this benefit
(Fournier et al., 2000).
1.5 Neuroprotective effects of lithium
For almost half a century, lithium has been the most widely used treatment for manic
depressive illness. Its clinical profile includes the anti-manic and anti-depressant actions as
well as prophylaxis of both mania and depression by reducing the frequency of the bipolar
episodes (Goodwin and Jamison, 1990; Birch, 1991).
Increasing evidence supports the notion that lithium has neuroprotective effects both in vitro
and in vivo. Lithium has been shown to protect against the toxic effects of a variety of insults
including glutamate, NMDA receptor activation, low potassium and toxic concentrations of
anticonvulsants in rat cerebellar granule cells (D’Mello et al., 1994; Nonaka et al., 1998a, b).
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receptor activation have also been demonstrated to occur in hippocampal and cortical neurons
in culture (Nonaka et al., 1998a). Other in vitro studies have indicated that lithium induces the
survival of PC12 cells after serum/nerve growth factor deprivation (Volonte and Rukenstein,
1993), and protects both PC12 cells and human neuroblastoma SH-SY5Y cells from ouabain
toxicity (Li et al., 1994). Several studies have provided evidence for neuroprotective effects of
lithium in vivo. Inouye et al. (1995) demonstrated that lithium pre-treatment delayed
radiation-induced apoptosis in the cells of the external granular layer after newborn mice were
exposed to gamma irradiation. Other studies have demonstrated that lithium attenuated both
the behavioral deficits and the reduction in choline acetyl transferase activity induced by
forebrain cholinergic system lesions (Pascual and Gonzalez, 1995) as well as the kainic acid-
induced reduction in glutamate decarboxylase levels and [3H]D-aspartate up-take (Sparapani
et al., 1997). In a rat model of ischemia, chronic lithium administration at higher doses
markedly reduced brain infarction and neurological deficits induced by occlusion of the
middle cerebral artery (Nonaka and Chuang, 1998).
In an attempt to elucidate the molecular mechanisms underlying the neuroprotection induced
by lithium, it has been shown that long-term treatment with lithium increases the expression
of the anti-apoptotic gene bcl-2. Lithium markedly increased the levels of  bcl-2 in rat frontal
cortex, hippocampus, and striatum in Wistar rats at therapeutically relevant concentrations
(Manji et al., 1999). Similar to the situation observed in rat brain in vivo, lithium produced a
marked increase in bcl-2 levels in SH-SY5Y cells and rat cerebellar granular cells (Chen and
Chuang, 1999). Moreover, lithium reduced the levels of the pro-apoptotic protein p53 both in
cerebellar granule cells (Chen and Chuang, 1999) and SH-SY5Y cells (Lu et al., 1999).
The effects of lithium on signaling pathways and transcription factors may contribute to its
neuroprotective effects. A bimodal mechanism of action of lithium is proposed. This model
describes the critical effect of lithium as that of a stabilizer of the magnitude of fluctuations of
signaling processes. This is achieved by balancing positive and negative regulators of
signaling processes which results in raising basal activities and diminishing maximal
activities, thereby stabilizing signaling activities within an optimal range and preventing
fluctuations either above or below this optimum. This model is applicable to many published
results concerning the activation of AP-1 DNA binding and cyclic AMP production (Jope ,
1999). It is important to emphasize that in addition to its neuroprotective effects, lithium is
well know to exert toxic effects at higher concentration in a variety of experimental
conditions (Hasgekar et al., 1996; Madiehe et al., 1995) as well as in humans (Goodwin and
9Jamison, 1990; Lenox and Manji, 1998). In general, the lithium toxicity is related to dose,
maturity of the cells, and interactions with other pharmacologic agents such as neuroleptics,
cholinomimetics and ACE inhibitors (D’Mello et al., 1994; Jope et al., 1986; Lenox and
Manji, 1998; Finley  et al., 1996).
1.6 Aims of the study
A number of actions of lithium have been described which support the hypothesis of a
synergistic interaction with RAS inhibitors such as ACE inhibitors. Lithium has been shown
to decrease blood pressure in SHR, possibly related to a decrease in plasma ACE activity (Das
and Bhargava, 1985). Synergistic effects may occur between lithium and ACE inhibitors at
the level of the intracellular phosphatidylinositol signaling system, particularly inositol 1,4,5-
triphosphate (IP-3). Lithium causes noncompetitive inhibition of monophosphatase, thus
reducing the breakdown of inositol phosphate to inositol and causing depletion of IP-3 in the
long-term. On the other hand, most of the AT1 receptor-mediated effects of Ang II are
mediated, at least in part, via IP-3. Lowering of IP-3 concentrations is seen at therapeutic
lithium concentrations. This effect may be particularly important in the central nervous
system because the inositol supply of neural cells is dependent on the local breakdown, in
contrast to extraneural cells that may use inositol from nutrients (Lehmann and Ritz, 1995).
ACE inhibitors reduce sympathetic transmission and facilitate parasympathetic nervous
transmission. Lithium acts in a similar fashion and would tend to act synergistically with ACE
inhibitors (Shionoiri, 1993; Matussek, 1972). Co-medication of lithium and ACE inhibitor
(high dose) can increase toxicity.
Recently we have demonstrated synergistic interactions between lithium and the ACE
inhibitor, captopril, in the prevention of stroke in SHRSP. Treatment of these rats with a low
dose of captopril (25 mg/kg per day) doubled the life expectancy when compared to control
rats although blood pressure was only slightly reduced. The addition of a low dose of lithium
(1 mmol/kg) to captopril dramatically increased survival when compared to captopril
treatment alone without an additional effect on blood pressure.
The present study was designed:
(1) to investigate whether a higher dose of captopril (50 mg/kg/day) can further increase
survival in salt-loaded SHRSP and whether the synergistic effect between lithium and the
ACE inhibitor on survival was preserved under these conditions.
(2) to investigate whether the AT1 receptor antagonist, telmisartan can prolong survival in
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salt-loaded SHRSP and whether the addition of lithium to the AT1 receptor antagonist has
synergistic effect on survival in these animals.
(3) to investigate the effects of chronic treatment of normotensive Wistar rats with lithium,
the ACE inhibitor captopril or a combination of both drugs on neurological deficits, infarct
volume as well as apoptotic and inflammatory events following acute focal ischemia induced
by unilateral middle cerebral artery occlusion with two days of reperfusion.
(4) to investigate the effects of chronic treatment of normotensive Wistar rats with the AT1
receptor antagonist, telmisartan and a combination of lithium and telmisartan on neurological
deficits, infarct volume as well as apoptotic and inflammatory events following acute focal
ischemia.
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2 Materials and Methods
2.1 Preparation of solutions and reagents
2.1.1 Solutions and reagents for immunhistochemistry and perfusion
10×PB (Phosphate Buffer): 11.5 g Na2HPO4.2H2O (Merck), 2 g KH2PO4 (Merck) and 2 g
KCl (Merck) were dissolved in 800 ml distilled water. The pH was adjusted to 7.4 and a final
volume of 1000 ml was achieved by adding distilled water.
PBS (Phosphate Buffered Saline): 8 g NaCl (Merck) were dissolved in 800 ml distilled
water. After addition of 100 ml PB (10×) solution, the pH was adjusted to 7.4 and a final
volume of 1000 ml was achieved by adding distilled water.
PBST: 5 ml Triton  X-100 (Sigma) was added to 995 ml PBS (1×, pH 7.4 )
30% Sucrose solution: 30g sucrose (Merck) was dissolved in 80 ml distilled water, then the
volume was adjusted to 100 ml.
4% Paraformaldehyde solution: 40 g paraformaldehyde (Merck) was dissolved in 900 ml
PB (1×, pH 7.4) at 60°C, then the volume was adjusted to 1000ml.
0.1% Paraformaldehyde solution: 10 ml 4% paraformaldehyde was added in 390 ml PBS
(1×, pH 7.4), and mixed.
0.1% Cresyl violet solution: 1g cresyl violet acetate (9-amino-5-imino-5H-benzo [α]-
phenoxazine actate salt, Sigma)  was added to 1000 ml distilled water. The solution was
vortexed for 2 days and filtered through filterpaper.
Acidic alcohol: 100 ml 10% acetic acid (Merck) was added in 900 ml 100% ethanol (Sigma),
and mixed.
0.1% Triton X-100 in 0.1% sodium citrate: 1 g sodium citrate (Merck) was dissolved in
1000 ml distilled water, then 1 ml Triton X-100 was added in the above solution, and mixed.
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5% Normal goat serum (NGS) in PBST: 50 µl normal goat serum (Vector) was added in
950 µl PBST, and mixed.
1%  Bovine serum albumin (BSA) in PBST: 1 g BSA (Sigma) was dissolved in 100 ml
PBST, and mixed.
0.3% Hydrogen peroxide: 10 µl 30% H2O2 (Merck) was added in 990 µl methanol (Merck),
and mixed.
3% Hydrogen peroxide: 100 µl 30% H2O2 was added in 900 µl methanol, and mixed.
ABC solution: VECTASTAIN  ELITE ABC Reagent (Vector): Two drops of  reagent A
were added to 5 ml PBS. After the addition of 2 drops of  reagent B, the solution was mixed
immediately. The solution was ready for use after 30 min.
DAB Reagent: 3, 3′-diaminobenzidine tablet sets (Sigma): Each Sigma Fast DAB tablets set
contains the following when dissolved in 5 ml deionized water: D 9292 DAB:  0.7 mg/ml;
U 1380 Urea hydrogen peroxide:  0.2 mg/ml and Tris buffer:  0.06 M.
TUNEL reaction solution: 50 µl TUNEL reaction solution included: 10 µl 5×TdT buffer;
2 µl CoCl2;   1µl terminal transferase (nucleoside-triphosephate: DNA
deoxynucleotidylexotransferase, TdT enzyme) and 37 µl TUNEL label (Nucleotide mix,
containing fluorescein-dUTP and dNTP). All of these reagents were purchased from Roche
Diagnostics GmbH.
2.1.2 Solutions for drug treatment
Lithium chloride solution: LiCl (Sigma) was solubilized in 0.9% saline. The concentration
of the LiCl solution was dependent on the weight of the rat and the application volume ( 1
mmol/kg, 0.5 ml/rat).
Captopril solution: Captopril (Wörwag GmbH & Co., Böblingen, Germany) was solubilized
in 0.9% saline.  The concentration of  the captopril solution was dependent on the weight of
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the rat and the application volume (50 mg/kg in SHRSP and 25 mg/kg in Wistar rats, 0.5
ml/rat).
Telmisartan solution: Telmisartan (Boehringer Ingelheim, Biberach an der Riss, Germany)
was solubilized in 0.9% saline with a few drops of 1 M NaOH (Merck), and the pH of the
solution  was adjusted to pH 9.5. The concentration of the telmisartan solution was dependent
on the weight of the rat and the application volume ( 0.3 mg/kg, 0.5 ml/rat) .
Captopril + LiCl solution: LiCl and captopril were solubilized to 0.9% saline. The
concentration of this solution was dependent on the weight of the rat and the application
volume (captopril: 50 mg/kg in SHRSP and 25 mg/kg in Wistar rats; LiCl: 1.0 mmol/kg, 0.5
ml/rat ).
Telmisartan + LiCl  solution: Telmisartan was solubilized in 0.9% saline with a few drops
of 1 M NaOH, then LiCl was added to the solution and the pH of the solution was adjusted to
pH 9.5. The concentration of this solution was dependent on the weight of the rat and the
application volume (telmisartan: 0.3 mg/kg; LiCl: 1.0 mmol/kg, 0.5 ml/rat ).
2.1.3 Solutions and reagents for albumin measurement
Buffer A: 3.2 g diethylmalonic acid (Aldrich), 8.77g NaCl , 1 ml 0.1 M EDTA (Roth) and 1
ml Tween 20 (Sigma) were dissolved in 800 ml distilled water. The PH was adjusted to 7.4 by
1 M KOH (Merck) and a final volume of 1000 ml was achieved by adding distilled water.  5g
gelatine (Sigma) was added to the above solution, and mixed at 37 °C.
Rat serum albumin (RSA) stock solution: 1g rat albumin (Sigma) was dissolved in 1000 ml
0.1 M NaHCO3 (Aldrich).
Coating solution: RSA stock solution was diluted 1:5000 with 0.1 M NaHCO3.
Conjugate solution: Albumin rat polyclonal antibody, anti-rat peroxidase conjugated sheep
IGG fraction to rat albumin (ICN) was diluted 1:9000 with buffer A.
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Substrate solution: 2 tablets of 3,3′,5,5′ tetramethylbenzidin-dihydrochlorid (Sigma) was
dissloved in 10 ml distilled water plus 10 ml buffer A. 4 µl 30% H2O2 was added in the above
solution, and mixed.
2.1.4 Solutions and reagents for plasma renin activity (PRA) measurement
Inhibitor cocktail: 1000 mg 1,10-phenanthroline-monohydrate (Merck) was dissolved in 2
ml ethanol (solution 1).  9.28 g Na2-EDTA (Merck) was dissolved in 160 ml distilled water
(solution 2). Solution 1 was added to solution 2 slowly, and mixed. 40 mg neomycin-sulfate
(Serva) was added to the above solution, and mixed.
Tris-maleic acid buffer: 9.086 g Tris (hydroxymethyl)-aminomethane (Merck) and 8.705 g
maleic acid (Merck) was dissolved  in 900 ml distilled water. The PH was adjusted to 6.5 and
a final volume of 1000 ml was achieved by adding distilled water.
0.1 M Tris-acetate-buffer (RIA buffer): 60.5 g Tris (hydroxymethyl)-aminomethane
(Merck) and 1 g neomycin-sulfate (Serva) was dissloved in 5 L distilled water and the PH was
adjusted to 7.4.
2.2 Animals
Male SHRSP bred at the Department of Pharmacology in Kiel and male Wistar rats (Charles
River, Germany) weighing 217 ± 15 g ( mean ± SD) were used for the experiments. All rats
were housed at constant humidity (60±5%) and temperature (25±1°C) and kept on a 12-hour
light/dark cycle. They were given free access to a standard  chow (Ssniff Spezialdiäten
GmbH, Soest, Germany) and were allowed to drink water ad libitum. The study was
performed in accordance with the guidelines for animal experiments of the University of Kiel
and was approved by the German governmental office dealing with animal protection.
2.3 Stroke prevention in SHRSP
2.3.1 Experimental protocol
At 8 weeks of age, the rats were randomized into six treatment groups based on body weight
and blood pressure, and they were housed in individual cages. At the same time the drinking
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water was permanently replaced by a 1% NaCl solution. All rats received a subcutaneous
injection (0.5 ml) once daily according to the following protocol.
Group 1: Isotonic NaCl (0.9%), n=12
Group 2: LiCl (1 mmol/kg), n=11
Group 3: Captopril (50 mg/kg), n=12
Group 4: Captopril (50 mg/kg) plus LiCl (1 mmol/kg), n=12
Group 5: Telmisartan (0.3 mg/kg), n=14
Group 6: Telmisartan (0.3 mg/kg) plus LiCl (1 mmol/kg), n=14
Treatment with telmisartan was initially started with 1 mg/kg per day. Due to significant
blood pressure reductions during the first 4 weeks of treatment, the dose of telmisartan was
decreased to 0.3 mg/kg per day.
All animals were inspected daily to detect neurological symptoms such as piloerection,
jumping, paralysis of anterior and/or posterior paws, aggression, prostration, loss of body
symmetry and convulsions. Body weight and salt water uptake were measured every 2-3 days.
After 5 weeks of treatment, 5 rats from each group were deeply anesthetized with chloral
hydrate (400 mg/kg) and intracardially perfused with ice cold 0.9% NaCl solution. The brains,
kidneys and hearts were removed and quickly frozen in dry ice and stored at −80°C. With the
remaining rats drug treatment was continued lifelong. Those rats which were very debilitated
(e.g.  edema, difficulty in breathing) and expected to die within the next two days were killed,
and hearts, kidneys and brains were removed as described above. Blood or 24 h urine samples
were collected at different time points for the measurement of the urinary and plasma
concentrations of Na+, K+and Li+, urinary albumin excretion and plasma renin activity.
2.3.2 Systolic blood pressure (SBP) measurement
SBP was measured by tail plethysmography with rats under light ether anesthesia.
Measurements were started before the onset of treatment and were continued in 1-4 week
intervals during the first 5 months of treatment and in 5-6 week intervals thereafter.
2.3.3 Determination of salt and water intake
Water and salt intake was measured by weighing the drinking solution over a 2-3 day period .
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2.3.4 Urine collection
After 11, 19, 27 and 37 weeks of treatment, all rats were housed individually in metabolic
cages with free access to rat chow and drinking water (1% NaCl solution) for 1 day
(adaptation period). The next day, urine was collected starting immediately after drug
treatment, and volume of urine and water intake during a 24 h period was measured. The
urine samples were centrifuged at 3000 g for 10 min, and the supernatant was stored at −20°C
until the measurement of urinary sodium, potassium, lithium and albumin concentrations.
2.3.5 Blood collection
After 21 and 39 weeks of treatment,  blood was collected from the retrobulbar venous plexus
after short ether anaesthesia (45-60 s), into an ice-cold 12.5 mM EDTA (Merck) solution
(50µl/ml blood). Blood samples were immediately centrifuged at 10.000 g and 4°C for 10
min, and then the plasma was separated and stored at –20 °C until the measurement of plasma
sodium, potassium and lithium concentrations, and plasma renin activity.
2.3.6 Determination of urinary and plasma sodium, potassium and lithium
concentrations
Sodium and potassium concentrations were measured by a flame photometer (Eppendorf
FCM 6341).
Lithium concentration was measured by a flame photometer (Eppendorf EFOX 5053)
2.3.7 Determination of urinary albumin concentration
The 96-well microtiter plates were coated by adding 100 µl/well coating solution. The plates
were wrapped in a plastic film and incubated for 3 h at 37°C and, subsequently, for 15 h at
4°C. After removing the coating solution, the microtiter plates were washed 3 times for 4 min
by adding 100 µl buffer A/well.
For the standard curve rat serum albumin stock solution (1 mg/ml) was diluted to yield
concentrations of: 0.00 - 0.03 - 0.05 - 0.07 - 0.10 - 0.2 - 0.3, 0.4 – 0.6 – 0.8 – 1.00 mg/l. 50µl
buffer A (zero value), 50 µl standard or 50µl sample (urine diluted with buffer A) were added
in each well. Measurements were carried out in a duplicate. After addition of 50 µl of
conjugate solution per well, the microtiter plates were incubated for 1 h at 37°C. Thereafter,
the plates were washed 4 times for 4 min with 100 µl/well of buffer A. 200 µl/well of the
substrate solution were added and incubated for 15 min. The reaction was stopped by adding
50 µl/well H2SO4 (Merck) (2 mol/l). The extinctions were measured at 450 nm with a ELISA-
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MRX-Plate Reader. The concentrations of albumin in urine samples were calculated with a
computer program (Dynex Revelation G 3.04) using an albumin standard curve. The 24 h
urinary albumin concentrations were expressed in mg/24 h taking into account the 24 h urine
volume.
2.3.8 Determination of plasma renin activity
PRA was measured by determining the level of Ang I generated during a 2h incubation period
at 37°C in the presence of an inhibitor cocktail. In brief: plasma (250 µl) was incubated with
50 µl of an inhibitor cocktail and 400 µl Tris-maleic acid buffer (75 mmol/L) in a water bath
at 37°C for 2 h. At three different time points - before (blank value), 1h and 2h after the start
of the incubation - 150 µl of the incubation mixture was added to ice-cold RIA buffer (150 µl)
and transferred into a water bath at 100°C for 5 min. Thereafter, the samples were put on ice
and centrifuged (6000 rpm) for 20 min at 4°C. The supernatant (100 µl) was used for the
measurement of Ang I by radioimmunoassay. The measurements were performed in
duplicate. Renin activity is expressed as ng Ang I/ml per h.
2.3.9 Cresyl violet staining
Coronal sections of 40 µm thickness were cut on a cryostat at − 20°C starting from bregma
+3.7 mm according to a rat brain atlas by Paxinos & Watson (1986).  Every 20th section (a
total of 12 sections) was mounted on a gelatine coated glass slide and stained with cresyl
violet for the detection of cell damage by light microscope. The cresyl violet staining was
performed  according to the protocol described in section 2.4.10.
2.3.10 TUNEL staining
Serial sections of 10 µm thickness from different brain areas (bregma –0.3 mm, -1.8 mm, -3.8
mm and -5.3 mm) were cut on a cryostat at −20 °C. The sections were mounted on gelatine
coated glass slides, and stained with TUNEL according to the protocol described in section
2.4.11 after the brain sections were incubated in 4% paraformaldehyde solution for 0.5 h.
TUNEL-positive cells were semiquantified in the sections on a scale of 0 to 4: 0, no or few
TUNEL-positive cells; 1, random TUNEL positive cells; 2, a discrete region of TUNEL-
positive cells; 3, many TUNEL-positive cells; and 4, the entire region is distributed with
TUNEL-positive cells.
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2.4 Intraluminal thread model of focal cerebral ischemia
The present study employed the intraluminal thread model for middle cerebral artery
occlusion ( MCAO ) with subsequent reperfusion. The intraluminal thread model of MCAO
in rats, first introduced by Koizumi et al. (1986) and later modified by Longa et al. (1989),
has become the most widely used model to study the pathophysiology and therapy of
permanent and transient focal cerebral ischemia. The model is minimally invasive and does
not require craniectomy.
2.4.1 Preparation of the occluding thread
The tip of the occluding thread (4/0, 1.5 metric, monofilament, ETHILON, ETHICON GmbH
& Co. KG, Germany) was coated with silicon (Provil, Bayer AG, Germany) to achieve a
diameter of about 0.25 mm at the distal end (5 mm). The silicon was allowed to harden before
use.
2.4.2 Surgery
The rat was anesthetized with an intraperitoneal injection of 4% chloral hydrate at a dose of
400 mg/kg (1ml/100g body weight). The right common carotid artery (CCA) was exposed via
a lateral neck incision and separated from the vagus nerve. Then both the external carotid
artery (ECA) and the internal carotid artery (ICA) were isolated from the adjacent tissue
under the operating microscope.  Before inserting the silicone-coated 4-0 nylon
monofilament, the right CCA and ECA were ligated with 4/0 suture. The filament was
inserted into CCA and gently advanced ≈ 17 mm via ICA from  the bifurcation of the CCA
and ECA, and it was monitored by Laser-Doppler flowmetry (LDF). The filament was
secured at the CCA by a tight ligation. Reperfusion was commenced 90 min after MCAO by
pulling out the monofilament. Rectal temperature was monitored and maintained between
37.0°C and 37.5°C with a heating pad throughout the surgical procedures.
2.4.3 Regional cerebral blood flow (rCBF) monitored by Laser-Doppler flowmetry
Insufficient MCAO and inadvertent subarachnoid hemorrhage (SAH) are the must common
complications of the intraluminal thread model. Continuous bilateral LDF is indispensable to
monitor adequate MCAO and is highly sensitive to recognize SAH (Robert et al, 1998).
rCBF was monitored in the cerebral cortex of each hemisphere in the supply territory of the
middle cerebral artery (MCA) by LDF (Periflux system 5000). The head of the rat was fixed
in the stereotaxic apparatus (David Kopf Instruments ). The scaple was incised on the midline,
19
and bilateral 1-mm burr holes were drilled 5.0 mm lateral and 1.0 mm posterior to the
bregma. The dura was left intact to prevent cerebrospinal fluid leakage. Tubes with internal
diameter 1.0 mm and external diameter 2.0 mm were fixed on the bilateral burr holes by
dental cement, and Laser-Doppler flowmeter probes were advanced to gently touch the intact
dura mater via the tubes. rCBF was continuously measured  during 30 min before ischemia,
immediately after the onset of MCA occlusion (0), during 90 min of ischemia, and during 30
min of reperfusion. The rCBF values were recorded every 10 min, and was calculated and
expressed as a percentage of the baseline values.
The filament was advanced until ipsilateral flow decreased to about 20% of baseline. If
ipsilateral LDF indicated premature reperfusion, the filament was immediately corrected.
Contralateral rCBF remained unchanged and fluctuated at about 100% of baseline. After
filament withdrawal, blood flow was restored to about 60-70% of baseline.
If ipsilateral LDF could not be reduced to 25% of baseline in rats,  the MCA of the rat was not
adequately occluded. If contralateral rCBF decrease initially after filament placement, and
ipisilateral LDF indicated a lack of reperfusion after filament withdrawal, the rats had
suffered SAH. All of these rats were excluded from the experiments.
2.4.4 Experimental design
Rats were divided randomly into six groups and were treated daily by a subcutaneous
injection (0.5 ml) according to the following protocol:
Group 1: Isotonic NaCl (0.9%), n=11
Group 2: LiCl (1 mmol/kg), n=10
Group 3: Captopril (25 mg/kg), n=9
Group 4: Captopril (25 mg/kg) plus LiCl (1 mmol/kg), n=8
Group 5: Telmisartan (0.3 mg/kg), n=10
Group 6: Telmisartan (0.3 mg/kg) plus LiCl (1 mmol/kg), n=11
Rats were treated once daily for two weeks. Two hours after the last drug application, rats
underwent MCAO for 90 min followed by reperfusion. Drug treatment was continued for
another 2 days after MCAO. Neurological evaluations were carried out 2 h after drug
treatment at day 1 and day 2 after MCAO. After the final neurological examination, rats were
killed by transcardial perfusion with PBS and  4% paraformaldehyde under deep anesthesia.
The brains were taken out. Infarct volume measurements and immunohistochemical
detections of TUNEL, activated caspase-3 and activated microglia were performed during the
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following days. In separate experiments, rats were divided in six groups (n=14 in vehicle-
treated group, and n=7 or 8 in drug-treated group) as described above. Blood pressure and
blood parameters such as pCO2, pO2, electrolytes, blood glucose and so on were measured at
different time points before, during and after MCAO as shown in Figure 1.
                                         Drug  treatment (1× daily, s.c. injection)
______________________________________________________________________
  ↓                                                                                                                                  ↓
Start of treatment                                                                                             End of treatment
                                                         MCAO                   Reperfusion
                           Anesthesia     _______________ |___________________________
                                            ↓    ↓                           ↓
                                                  0       30      60      90      120    150  minutes
    |_______|____//____|_______|_______|___|___|___|___|___|___|___|___|___|___|___|_________//_|_______|_______
   1         2             13       14                                                                               15       16     days
                                          ↑_↑______↑  ________↑____↑              ________↑____↑_______
                                               Blood collection                                  Neurological examination
                                                   ---------- →
                                           ↑___________________________________
                                                                       MAP
                                                                                                                 _____________↑____
                                                                                                                 Infarct volume and
                                                                                                                 immunohistochemical
                                                                                                                 detection
Figure 1.  Experimental protocol
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2.4.5 Implantation of the femoral artery catheter
Two days before MCAO, a polyethylene catheter (pp-50) was inserted through the femoral
artery into the abdominal aorta under chloral hydrate (400 mg/kg, i.p.) anesthesia. The
catheter was filled with heparinized saline, passed through a subcutaneous tunnel, sealed, and
secured at the back of the neck. The arterial catheter was used for blood pressure
measurement, and blood sample withdrawal.
2.4.6 Measurement of mean arterial blood pressure (MAP)
Measurement of MAP was performed via the arterial catheter with use of a pressure
transducer (DTX/Plus, Spectramed ) connected to a pressure processor (Gould) coupled to a
Gould Brush recorder. The analog output signal of MAP from the pressure processor was
digitalized and then processed with a computer program.
2 hours after treatment, the measurement was started when the rat was resting and when basal
MAP was stable. After baseline measurement, the rat was injected intraperitoneally chloral
hydrate (400mg/kg body weight) and the MAP was recorded after it was stable. Then the
MAP was continuously recorded before MCAO, during MCAO and after reperfusion.
2.4.7 Blood collection for the measurement of blood parameters
The blood was withdrawn from the arterial catheter into capillary tubes (Standard heparinized,
tube volume 115 µl) at different time points:
(1) 2 h after treatment when the rats were conscious;
(2) 10 min after anesthesia before MCAO;
(3) 30 min after MCAO;
(4) 90 min after MCAO;
(5) 30 min following reperfusion.
At each time point the following physiological parameters in blood samples were measured
by RADIOMETER ABL 700 SERIE : pH, pCO2, pO2, plasma glucose concentration (cGlu),
plasma lactate concentration (cLac), plasma hemoglobin concentration (ctHb) and plasma
concentrations of some electrolytes: cK+, cNa+, cCa2+,  cCl−.
2.4.8 Evaluation of neurological deficits
The neurologic status of each rat was evaluated carefully 24 h and 48 h after MCAO by an
observer who had no knowledge of the procedure that the rat had undergone. Two
neurological grading systems were used to assess the effects of ischemia.
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2.4.8.1 A grading scale of 0-3 developed by Bederson et al. (1986)
The method includes the evaluation of the grade of the forelimb flexion contralateral to the
injured hemisphere, resistance to lateral push, and observation for circling behavior (Table 1).
These tests were conducted sequentially, if a rat exhibited the appropriate behavior at one step
but not at the subsequent step, it was graded as the former. Rats with no observable deficits
were graded 0; rats displaying circling behavior together with forelimb flexion and decreased
resistance to lateral push were graded 3.
Table 1. The neurological deficit examination system with grading scale of  0-3
______________________________________________________________________
Normal          grade 0:  no observable deficit
Moderate       grade 1:  forelimb flexion
Severe           grade 2:  forelimb flexion, decreased resistance to lateral push without
                                     circling
                      grade 3:  the same behavior as grade 2 with circling
_______________________________________________________________________
2.4.8.2 A grading scale of 3-18 developed by Garcia et al. (1995b)   
The neurobehavioral study consisted of the following six tests:
1. Spontaneous activity
The animal was placed in a plastic cage and was observed for 5 minutes. The rat’s activity
was assessed by its ability to approach all four walls of the cage. Scores indicate the
following: 3, rat moved around, explored the environment and approached at least three walls
of the cage; 2, slightly affected rat moved about in the cage but did not approach all sides and
hesitated to move, although it eventually reached at least one upper rim of the cage; 1,
severely affected rat did not rise up at all and barely moved in the cage; and 0, rat did not
move at all.
2. Symmetry in the movement of four limbs
The rat was held in the air by the tail to observe symmetry in the movement of the four limbs.
Scores indicate the following: 3, all four limbs extended symmetrically; 2, limbs on left side
extended less or more slowly than those on the right; 1, limbs on left side showed minimal
movement; and 0, forelimb on left side did not move at all.
3. Forepaw outstretching
The rat was brought up to the edge of the table and made to walk on forelimbs while being
held by the tail. Symmetry in the outstretching of both forelimbs was observed while the rat
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reached the table and the hindlimbs were kept in the air. Scores indicate the following: 3, both
forelimbs were outstretched, and the rat walked symmetrically on forepaws; 2, left side
outstretched less than the right, and forepaw walking was impaired; 1, left forelimb moved
minimally; and 0, left forelimb did not move.
4. Climbing
The rat was placed on the wall of a wire cage. Normally the rat uses all four limbs to climb up
the wall. When the rat was removed from the wire cage by pulling it off by the tail, the
strength of attachment was noted. Scores indicate the following: 3, rat climbed easily and
gripped tightly to the wire; 2, left side was impaired while climbing or did not grip as hard as
the right side; and 1, rat failed to climb or tended to circle instead of climbing.
5. Body proprioception
The rat was touched with a blunt stick on each side of the body, and the reaction to the
stimulus was observed. Scores indicate the following: 3, rat reacted by turning head and was
equally startled by the stimulus on both sides; 2, rat reacted slowly to stimulus on left side;
and 1, rat did not respond to the stimulus placed on the left side.
6. Response to vibrissae touch
A blunt stick was brushed against the vibrissae on each side; the stick was moved toward the
whiskers from the rear of the animal to avoid entering the visual fields. Scores indicate the
following: 3, rat reacted by turning head or was equally startled by the stimulus on both sides;
2, rat reacted slowly to stimulus on left side; and 1, rat did not respond to stimulus on the left
side.
The score given to each rat at the completion of the evaluation is the summation of all six
individual test scores. The minimum neurological score is 3 and the maximum is 18 (Table 2).
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Table 2. The neurological deficit examination system with a scale of 3-18
_________________________________________________________________________________________
                                                                                          Score
                               __________________________________________________________________________
     Test                                   0                               1                                 2                                  3
__________________________________________________________________________________________
Spontaneous activity    No movement        Barely moves          Moves but does not            Moves  and
(in cage for 5 min)                                                                       approach at least 3             approaches at  least
                                                                                                     sides of cage                      3 sides of cage
Symmetry of                 Left side:                Left side:                 Left side:                           Both sides:  move
movements                   no  movement        slight movement      moves slowly                    symmetrically
(four limbs)
Symmetry of                Left side: no            Left side: slight        Left side: moves and         Symmetrical
forelimbs                      movement, no         movement to            outreaches less than           outreach
(outstretching while     outreaching             outreach                    right side
held by tail)
Climbing wall of                                          Fails to climb            Left side is weak              Normal climbing
wire cage
Reaction to touch                                         No response on         Weak response on            Symmetrical
on either side of                                            left side                     left side                            response
trunk
Response to vibrissae                                   No response on         Weak response on            Symmetrical
touch                                                             left side                     left side                             response
__________________________________________________________________________________________
2.4.9 Tissue processing
Two days after MCAO, rats were deeply anesthetized with chloral hydrate (400 mg/kg) and
intracardially perfused with ice cold PBS followed by 4% paraformaldehyde solution. The
brains were removed and kept in 4% paraformaldehyde solution overnight for fixation of
brain tissue. On the next day the brains were cryoprotected in 30% sucrose for 3-4 days at 4
°C. Coronal sections of 40 µm thickness were cut from bregma +3.7 mm to bregma –6.7 mm
according to a rat brain atlas (Paxinos & Watson , 1986) on a cryostat at −20 °C. One of every
20 slices was mounted on a gelatine coated glass slide for the measurement of infarct size. For
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immunohistochemical detection, serial slices from different brain areas (bregma –0.3 mm and
-1.8 mm) were immersed in 0.1% paraformaldehyde solution as free-floating sections.
TUNEL staining, caspase-3 staining and activated microglia staining were performed within
1-2 weeks.
2.4.10 Measurement of the infarct size
Sections (40 µm) were stained with cresyl violet according to the following protocol:
The brain sections were
1. washed in distilled water for 1 min.
2. incubated in 100% ethanol for 3 min.
3. incubated in 100% xylol for 15 min.
4. incubated in 100% ethanol for 3 min.
5. washed in distilled water for 1 min.
6. stained in 0.1% cresyl violet for 5 min.
7. washed in distilled water for 1 min.
8. washed in acidic alcohol for a few seconds until the staining was optimal.
9. washed in distilled water for 1 min.
The coverslips were mounted using pertex after dehydration.
The stained sections were analyzed at 14 predetermined levels (bregma +3.7, +2.9, +2.1, +1.3,
+0.5, −0.3, −1.1, −1.9, −2.7, −3.5, −4.3, −5.1, −5.9 and −6.7 mm). The stained slices were
photographed by a digital camera (Victor Company of Japan, Color Video Camera) and the
border between infarcted and non-infarcted area was outlined with the Leica image analysis
system. The area of infarction was measured on each slice, and the infarct volume was
calculated by multiplying the sum of the infarct area with the distance between sections
(Zhang et al. 2001).
In addition, contralateral and ipsilateral hemisphere areas were measured, and the difference
between ipsilateral and contralateral areas in each section was used to calculate the edema
volume (Justicia et al. 1999). There is a possibility that infarct volume is influenced by brain
edema, therefore the percentage of hemisphere suffering infarction was calculated  using the
formula of Swanson et al. (1990), taking cerebral edema into account:
%infarct = 100×( VC-VL)/ VC
%infarct = the  percentage of  the hemisphere that had undergone a cerebral infarction
VC = normal volume of the contralateral hemisphere
VL = normal volume in the ipsilateral hemisphere
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Vc ~ d × ∑in AC
 VL ~ d × ∑in AL
d = distance between sections
AC = area of normal tissue of the contralateral hemisphere on section i
AL = area of normal tissue of the ipsilateral hemisphere on section i
2.4.11 Immunohistochemistry
2.4.11.1 TUNEL staining
TUNEL staining was performed according to the following protocol:
The brain sections were
1. incubated in freshly prepared 0.3% H2O2-methanol solution for 1 h at room temperature
(RT) to block endogenous peroxide activity.
2. washed in  PBS, two times for 5 min each.
3. incubated in permeabilisation solution (0.1% Triton X-100 in 0.1% sodium citrate) for 5
min at RT.
4. washed in  PBS, two times for 5 min each.
5. incubated with TUNEL reaction solution for 1 h at 37°C.
6.   washed in  PBS, three times for 5 min each.
7. incubated with TUNEL POD (Converter-POD: anti-fluorescein antibody, Fab fragment
from sheep, conjugated with peroxidase, Roche Diagnostics GmbH) for 30 min at 37°C to
detect fluorescein-dUTP.
8. washed in  PBS, three times for 5 min each.
9. incubated in DAB solution until staining was optimal as determined by light microscopic
examination.
10.  washed in  PBS, three times for 5 min each.
11.  mounted on gelatine coated slides and dried at RT.
Coverslips were mounted using pertex after dehydration.
Negative control staining was performed using distilled water instead of terminal transferase
for the preparation of TUNEL reaction solution.
Total of 6 rats were used for TUNEL staining in the each group. TUNEL-labeled cells were
counted in the parietal cortex using a computer programm (Leica QWin). Three random and
non-overlapping regions (375×500 µm) were sampled at the cortical border of the TUNEL-
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positive area (Figure 2). Only densely labeled cells were considered as positive apoptotic
cells, and cells with light diffuse labeling suggesting necrosis were not counted (Figure 3).
2.4.11.2 Activated Caspase-3
Activated caspase-3 was staining according to the following protocol:
The brain sections were
1.  washed in PBST, three times for 5 min each.
2.  incubated in freshly prepared 0.3% H2O2-methanol solution for 30 min
     at RT.
3.  washed in PBST, two times for 5 min each.
4.  washed in 5% NGS in PBST for 15 min.
5.  incubated with the primary antibody (Cleaved Caspase-3 [17 KDa] antibody, Cell
    Signaling Technology ) diluted in PBST/1% BSA (1:100) overnight at 4°C.
6.  washed in PBST, three times for 5 min each.
7.  incubated with the secondary antibody ( Anti-Rabbit Ig(H+L), biotinylated, Vector)
     diluted in PBST (5 µg/ml) for 1 h at 37°C.
8.  washed in PBST, three times for 5 min each.
9.  incubated in ABC solution for 45 min at 37°C.
10. washed in PBS, three times for 5 min each.
11. incubated in DAB solution until staining was optimal.
12. washed in PBS, three times for 5 min each.
13. mounted on gelatine coated slides and dried at RT
Coverslips were mounted using pertex after dehydration.
Negative control staining consisted of omission of the primary antibody in the PBST/1% BSA
solution.
Total of 6 rats were used for activated caspase-3 staining in the each group. Caspase-3 labeled
cells were counted in the parietal cortex using a computer program (Leica QWin). Three
random and nonoverlapping regions (375×500 µm) were sampled at the cortical border of the
caspase-3 positive area (Figure 2).
2.4.11.3 Activated microglia
Activated microglia was stained according to the following protocol:
The brain sections were
1.   washed in PBST, three times for 5 min each.
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2. incubated in freshly prepared 3% H2O2-methanol solution for 5 min at RT.
3. washed in PBST, two times for 5 min  each.
4. washed in 5% NGS in PBST for 15 min.
5. incubated with the primary antibody (Mouse Anti Rat ED1, Serotec Product Datasheet)
diluted in PBS (1:300) for 2 nights at 4°C.
6. washed in PBS, three times for 5 min each.
7. incubated with the secondary antibody (Anti-Mouse Igg (FC), biotin conjugate, developed
in goat, adsorbed with human IGg, Sigma) diluted in PBS (1:300) for 1 h at 37°C.
8. washed in PBS, three times for 5 min each.
9. incubated in ABC solution for 45 min at 37°C.
10. washed in PBS, three times for 5 min each.
11. incubated in DAB solution until staining was optimal.
12. washed in PBS, three times for 5 min each.
13. mounted on gelatine coated slides and dried at RT
Coverslips were mounted using pertex after dehydration.
Negative control staining consisted of omission of the primary antibody in the PBS  solution.
Total of 6 rats were used for activated microglia staining in each group. Actived microglia
were counted in the parietal cortex using a computer programm (Leica QWin). Three random
and nonoverlapping regions (375×500 µm) were sampled at the cortical border of the
activated microglia positive area (Figure 2).
2.5 Statistical analysis
All data are expressed as mean ± S.E.M (standard error of the mean). Comparisons among the
vehicle-treated group and drug-treated groups were performed by one-way analysis of
variance (ANOVA) followed by a post-hoc test (Bonferroni). Comparisons on physiological
parameters between the vehicle-treated group and each drug-treated group were performed by
one-way analysis of variance (ANOVA) followed by a post-hoc test (Dunnett). Mortality was
compared among the vehicle-treated group and drug-treated groups using the Kaplan-Meier
analysis of survival followed by Log-rank Test (Cox-Mantel). Values of  p<0.05 were
considered  to be statistically significant.
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Figure 2. TUNEL (+) cells, activated caspase-3 (+) cells and activated microglia were
counted in the parietal cortex using a computer program (Leica QWin). Three random and
nonoverlapping regions (375×500 µm) were selected in the border of the ischemic cortical
area. Scale bar, 500 µm.
Figure 3. TUNEL staining in the ischemic brain. Only densely labeled cells (arrows) were
considered as positive apoptotic cells, and cells with light diffuse labeling indicating necrosis
(arrowheads) were not counted. Scale bar, 100 µm.
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3. Results
3.1 Stroke prevention in SHRSP
3.1.1 Survival rate
Average survival was 39 days (range, 31 to 51 days after the start of salt loading) in rats
treated with vehicle and 36 days (range, 28 to 56) in rats treated with LiCl. Most rats in both
groups died between 4-6 weeks after salt loading and there was no difference in survival rate
between these two groups. Captopril (50 mg/kg perday) treatment markedly increased average
survival to 247 days (range, 93 to 366). The addition of LiCl to captopril did not further
increase the survival rate. The average survival in the captopril plus LiCl treated group was
225 days (range, 117 to 282) (Figure 4, Table 3).
Table 3. The effect of treatment with LiCl, captopril and captopril plus LiCl on survival in
SHRSP after the start of salt loading
______________________________________________________________________
                         n                 Average survival, day (ranges)
Vehicle 7                            39    (31-51)
LiCl                      6                            36    (28-56)
Captopril        7                            247  (93-366)
Cap.+LiCl               7                            225  (117-282)
___________________________________________________________
Telmisartan (intially 1.0 mg/kg per day, finally 0.3 mg/kg per day) treatment markedly
increased average survival to 310 days (range, 60 to 405). The addition of LiCl to telmisartan
did not further increase survival. The average survival in the combination treated group was
317 days (range, 282 to 366) (Figure 5, Table 4).
Table 4. The effect of treatment with LiCl, telmisartan or telmisartan plus LiCl on survival in
SHRSP after the start of salt loading
________________________________________________________________________
                              n              Average survival, day (ranges)
Vehicle              7                          39    (31-51)
LiCl                       6                          36    (28-56)
Telmisartan            9                          310  (60-405)
Telmi.+LiCl           7                          317  (282-366)
______________________________________________________________
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Figure 4. Effect of LiCl, captopril and captopril plus LiCl on survival rate in salt-loaded SHRSP.
From 8 weeks of age, SHRSP were treated subcutaneously with vehicle (0.9% NaCl), LiCl (1.0
mmol/kg/d), captopril (50 mg/kg/d) and captopril plus LiCl lifelong, and at the same time drinking
water was permanently replaced with 1% NaCl.
Figure 5. Effect of LiCl, telmisartan and telmisartan plus LiCl on survival rate in salt-loaded
SHRSP. From 8 weeks of age, SHRSP were treated subcutaneously with vehicle (0.9% NaCl), LiCl
(1.0 mmol/kg/d), telmisartan (initially 1.0 mg/kg/d, and finally 0.3 mg/kg/d) and telmisartan plus LiCl
lifelong, and at the same time drinking water was permanently replaced with 1% NaCl.
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3.1.2 Systolic blood pressure
SBP was similar in the rats of all groups at the beginning of the experiment. SBP increased in
saline- and captopril-treated rats at 12 weeks of age. Thereafter, SBP levels in rats treated
with captopril remained at a level of 180-220 mm Hg. In LiCl- and captopril plus LiCl-treated
rats SBP did not increase during the first 4 weeks of treatment. Thereafter, SBP in captopril
plus LiCl-treated rats was highly variable during the remaining treatment period and ranged
from 150-220 mmHg. The addition of LiCl to captopril reduced blood pressure when
compared to captopril alone, with significant differences in SBP levels at 18 weeks (P<0.01),
19 weeks (P<0.01), 21 weeks (P<0.05) and 22 weeks (P<0.05) of age (Figure 6).
Figure 6. Effect of LiCl, captopril and captopril plus LiCl on systolic blood pressure (SBP) in
salt-loaded SHRSP. From 8 weeks of age, SHRSP were treated subcutaneously with vehicle (0.9%
NaCl), LiCl (1.0 mmol/kg/d), captopril (50 mg/kg/d) and captopril plus LiCl lifelong. ∗ P<0.05, ∗∗
P<0.01, versus vehicle-treated animals.
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Treatment with telmisartan was initially started with 1 mg/kg per day. At 12 weeks of age (4
weeks of treatment) SBP in LiCl-, telmisartan- and telmisartan plus LiCl-treated rats
remained below the control level, and telmisartan significantly reduced SBP compared to
vehicle (P<0.01). Due to significant blood pressure reductions, the dose of telmisartan was
decreased to 0.3 mg/kg per day thereafter. The blood pressure increased gradually after dose
adjustment, but remained below 220 mm Hg. SBP was comparable in the telmisartan- and
telmisartan plus LiCl-group throughout the remaining treatment period (Figure 7).
Figure 7. Effect of LiCl, telmisartan and telmisartan plus LiCl on systolic blood pressure (SBP)
in salt-loaded SHRSP. From 8 weeks of age, SHRSP were treated subcutaneously with vehicle (0.9%
NaCl), LiCl (1.0 mmol/kg/d), telmisartan (initially 1.0 mg/kg/d, and finally 0.3 mg/kg/d) and
telmisartan plus LiCl lifelong. ∗∗ P<0.01 versus vehicle-treated animals.
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3.1.3 Body weight
Body weight, as an index of growth, was comparable in all groups until 3 weeks of treatment.
Then, the rats in the vehicle- and LiCl-groups failed to increase their body weight and showed
a decrease. In contrast, the body weights of rats in the captopril- and captopril plus LiCl-
groups continued to exhibit a regular age-related increase. After a long term treatment, large
body weight values were observed in some rats with huge edema several days before death,
especially in the captopril plus LiCl-group (Figure 8). A similar progress in body weights was
observed in rats from the telmisartan – and telmisartan plus LiCl-groups. These rats continued
to exhibit a regular age-related increase. Again,  large body weight values were observed in
some rats with huge edema several days before death (Figure 9).
Figure 8. Effect of LiCl, captopril and captopril plus LiCl on body weight in salt-loaded SHRSP.
From 8 weeks of age, SHRSP were treated subcutaneously with vehicle (0.9% NaCl), LiCl (1.0
mmol/kg/d), captopril (50 mg/kg/d) and captopril plus LiCl lifelong.
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Figure 9. Effect of LiCl, telmisartan and telmisartan plus LiCl on body weight in salt-loaded
SHRSP. From 8 weeks of age, SHRSP were treated subcutaneously with vehicle (0.9% NaCl), LiCl
(1.0 mmol/kg/d), telmisartan (initially 1.0 mg/kg/d, and finally 0.3 mg/kg/d) and telmisartan plus LiCl
lifelong.
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3.1.4 Water intake and urinary volume
Water and salt intake were similar in all groups during the first 3 weeks of treatment.
Thereafter, water and salt intake increased in the vehicle- and LiCl-groups, especially in the
rats with symptoms of stroke. Water and salt intake was comparable in the rats treated with
captopril and captopril plus LiCl during the first 8 weeks of treatment. Thereafter water and
salt intake in captopril plus LiCl-treated rats remained at  higher levels compared to captopril-
treated rats (Figure 10 ). Measurements of 24 h salt water intake and urinary water excretion
at 11, 19, 27, and 37 weeks of treatment from rats in metabolic cages are shown in Figure 11.
SHRSP treated with captopril plus LiCl exhibit a higher water intake and urine excretion than
rats treated with captopril alone. There was a significant difference in the water intake at 27
weeks of treatment (P<0.05) and in the urine excretion at  11 weeks (P<0.05) and 27  weeks
of treatment (P<0.01).
Figure 10. Effect of LiCl, captopril and captopril plus LiCl on salt water intake (1% NaCl) in
SHRSP. From 8 weeks of age, SHRSP were treated subcutaneously with vehicle (0.9% NaCl), LiCl
(1.0 mmol/kg/d), captopril (50 mg/kg/d) and captopril plus LiCl lifelong.
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Figure 11. Effect of LiCl, captopril and captopril plus LiCl on salt water intake (A) and urinary
excretion (B) in salt-loaded SHRSP. From 8 weeks of age, SHRSP were treated subcutaneously with
vehicle (0.9% NaCl), LiCl (1.0 mmol/kg/d), captopril (50 mg/kg/d) and captopril plus LiCl lifelong.
At different treatment periods, rats were housed individually in metabolic cages for 1 day (adaptation
period). The next day, urine was collected starting immediately after drug treatment, and volume of
urine and water intake during a 24 h period were measured. ∗ P<0.05, ∗∗ P<0.01 versus vehicle-
treated animals.
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Water and salt intake were comparable in telmisartan- and telmisartan plus LiCl-treated rats
during the first 30 weeks of treatment. Thereafter, water and salt intake increased in animals
treated with telmisartan plus LiCl (Figure 12). Measurements of 24 h salt water intake and
urinary water excretion from rats in metabolic cages are shown in Figure 13. SHRSP treated
with telmisartan plus LiCl exhibited a significantly higher water intake at 27 weeks of
treatment and an increased urine excretion at 19 and 27 weeks of treatment compared to rats
treated with telmisartan alone (P<0.05).
Figure 12. Effect of LiCl, telmisartan and telmisartan plus LiCl on salt water intake (1% NaCl)
in SHRSP. From 8 weeks of age, SHRSP were treated subcutaneously with vehicle (0.9% NaCl), LiCl
(1.0 mmol/kg/d), telmisartan (initially 1.0 mg/kg/d, and finally 0.3 mg/kg/d) and telmisartan plus LiCl
lifelong.
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Figure 13. Effect of LiCl, telmisartan and telmisartan plus LiCl on salt water intake (A) and
urinary excretion (B) in salt-loaded SHRSP. From 8 weeks of age, SHRSP were treated
subcutaneously with vehicle (0.9% NaCl), LiCl (1.0 mmol/kg/d), telmisartan (initially 1.0 mg/kg/d,
and finally 0.3 mg/kg/d) and telmisartan plus LiCl lifelong. At different treatment periods, rats were
housed individually in metabolic cages for 1 day (adaptation period). The next day, urine was
collected starting immediately after drug treatment, and volume of urine and water intake during a 24
h period were measured. ∗ P<0.05 versus vehicle-treated animals.
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3.1.5 The concentrations of sodium and potassium in plasma and their urinary
excretions
Plasma levels of sodium and potassium were not different between captopril- and captopril
plus LiCl-treated rats (Table 5).  The urinary excretion of sodium and potassium in these two
groups is shown in Figure 14. After 27 weeks of treatment, rats treated with captopril plus
LiCl excreted more sodium than rats treated with captopril alone (17.49 ± 1.21 mmol/day
versus 11.66 ± 1.35 mmol/day, P<0.05). After 11, 19 and 37 weeks of treatment, the addition
of LiCl to captopril slightly increased the excretion of sodium, but there was no significant
difference between these two groups. Urinary excretion of potassium was not different
between these two groups.
Table 5. The concentration of Na+ and K+ in the plasma of SHRSP at 21 weeks of treatment
with captopril and captopril plus LiCl
__________________________________________________________________
Group                    n               Na+ (mmol/L)                   K+ (mmol/L)
__________________________________________________________________
Captopril               6              179.03 ± 2.25                    4.98 ± 0.15
Cap.+Li.                5              170.62 ± 6.71                    4.95 ± 0.22
__________________________________________________________________
Values are mean ± S.E.M of n rats.
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Figure 14. Effect of LiCl, captopril and captopril plus LiCl on urinary excretion of Na+ (A) and
K+ (B) in salt-loaded SHRSP. From 8 weeks of age, SHRSP were treated subcutaneously with
vehicle (0.9% NaCl), LiCl (1.0 mmol/kg/d), captopril (50 mg/kg/d) and captopril plus LiCl lifelong.
At different treatment periods, rats were housed individually in metabolic cages, and urine was
collected during a 24 h period for the measurement of sodium and potassium concentrations. ∗ P<0.05
versus captopril-treated animals.
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Plasma levels of sodium and potassium were not different between telmisartan- and
telmisartan plus LiCl-treated rats (Table 6).  The urinary excretion of sodium and potassium
in the two groups are shown in Figure 15. At 27 weeks of treatment, rats treated with
telmisartan in combination with lithium excreted more sodium than rats treated with
telmisartan alone (17.10 ± 1.36 mmol/day versus 12.87 ± 0.95 mmol/day, P<0.05). At 11, 19
and 37 weeks of treatment, the urinary excretions of sodium in the both groups were
comparable. Urinary excretion of potassium was not different between these two groups.
Table 6. The concentration of Na+ and K+ in the plasma of SHRSP at 21 weeks of treatment
with telmisartan and telmisartan plus LiCl
__________________________________________________________________
      Group              n             Na+ (mmo/L)                    K+ (mmo/L)
__________________________________________________________________
Telmisartan    8            174.01 ± 3.77                    4.70 ± 0.13
Telmi.+Li.         7            167.84 ± 4.92                    4.68 ± 0.13
___________________________________________________________________
Values are mean ± S.E.M of n rats.
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Figure 15. Effect of LiCl, telmisartan and telmisartan plus LiCl on urinary excretion of Na+ (A)
and K+ (B) in salt-loaded SHRSP. From 8 weeks of age, SHRSP were treated subcutaneously with
vehicle (0.9% NaCl), LiCl (1.0 mmol/kg/d), telmisartan (initially 1.0 mg/kg/d, and finally 0.3
mg/kg/d) and telmisartan plus LiCl lifelong. At different treatment periods, rats were housed
individually in metabolic cages, and urine was collected during a 24 h period for the measurement of
sodium and potassium concentrations. ∗ P<0.05 versus telmisartan-treated animals.
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3.1.6 Lithium concentration in plasma and urine
Daily subcutaneous injection of LiCl in combination with captopril caused plasma Li+-
concentrations of 0.66 ± 0.01 mmol/L (n=5) at 21 weeks of treatment. At 39 weeks of
treatment the Li+-concentration was 0.86 ± 0.21 mmol/L (n=3). In one rat the Li+-
concentration was 1.28 mmol/L, much higher than in the other two rats (0.63 and 0.66
mmol/L). Li+ was below detection limit or 0.02 ± 0.01 mmol/L at 21 and 39 weeks of
treatment in captopril-treated rats (Table 7).  The urinary excretion of Li+ in the two groups is
shown in Table 8. Daily lithium excretion in urine had a tendency of increase in the captopril
plus LiCl-group, and lithium excretion at 37 weeks of treatment was significantly higher than
at 11 weeks of treatment (0.268 ± 0.084 mmol/day versus 0.091 ± 0.010 mmol/day, P<0.05).
Table 7.  The concentration of Li+ in the plasma of SHRSP at 21 and 39 weeks of treatment
with captopril and captopril plus LiCl
______________________________________________________________
                                                                  Li+  ( mmol/L)
 Group                            21  weeks     (n)                         39  weeks     (n)
______________________________________________________________
Captopril                              −             (6)                        0.02 ± 0.01    (3)
Cap.+Li.                        0.66 ± 0.01    (5)                        0.86 ± 0.21    (3)
______________________________________________________________
Values are mean ± S.E.M of n rats.
Table 8. Daily  Li+ excretion in the urine of SHRSP at 11, 19, 27 and 37 weeks of treatment
with  captopril and captopril plus LiCl
__________________________________________________________________________________________
                                                                         Li+   (mmol/day)
Group                11  weeks  (n)         19  weeks   (n)          27  weeks   (n)         37  weeks    (n)
___________________________________________________________________________
Captopril      0.003 ± 0.000 (7)     0.002 ± 0.000 (6)     0.003 ± 0.000 (6)    0.003 ± 0.000   (3)
Cap.+Li.       0.091 ± 0.010 (7)     0.124 ± 0.018 (6)     0.165 ± 0.055 (5)    0.268 ± 0.084∗ (4)
___________________________________________________________________________
Values are mean ± S.E.M of n rats. ∗ P<0.05,  versus Cap. + Li. group at 11 weeks of treatment.
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Daily subcutaneous injection of LiCl in combination with telmisartan caused plasma Li+-
concentrations of 0.62 ± 0.03 mmol/L (n=7) and 0.56 ± 0.02 mmol/L (n=7) at 21 and 39
weeks of treatment, respectively. Li+ was below detection limit or 0.04 ± 0.00 mmol/L at 21
and 39 weeks of treatment in the telmisartan-treated rats (Table 9).  The urinary excretion of
Li+ in the both groups is shown in Table 10. Daily urinary lithium excretions were comparable
at the different time points.
Table 9. The concentration of Li+ in the plasma of SHRSP at 21 and 39 weeks of treatment
with telmisartan and telmisartan plus LiCl
_____________________________________________________________
                                                             Li+  (mmol/L)
Group                         21  weeks   (n)                          39  weeks    (n)
______________________________________________________________
Telmisartan                    −          (8)                          0.04 ± 0.00   (7)
Telmi.+Li.            0.62 ± 0.03   (7)                          0.56 ± 0.02   (7)
______________________________________________________________
Values are mean ± S.E.M of n rats.
Table 10. Daily  Li+ excretion in the urine of SHRSP at 11, 19, 27 and 37 weeks of treatment
with  telmisartan and telmisartan plus LiCl
__________________________________________________________________________________________
                                                                     Li+   (mmol/day)
Group                  11  weeks    (n)      19  weeks     (n)       27  weeks    (n)       37  weeks    (n)
___________________________________________________________________________
Telmisartan      0.014 ± 0.001 (8)    0.013 ± 0.001 (8)    0.013 ± 0.002 (8)    0.010 ± 0.002 (7)
Telmi.+Li         0.149 ± 0.019 (9)    0.125 ± 0.012 (7)    0.134 ± 0.025 (7)    0.158 ± 0.022 (7)
___________________________________________________________________________
Values are mean ± S.E.M of n rats.
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3.1.7 Daily urinary excretion of albumin
Daily urinary excretion of albumin in the rats treated with captopril plus LiCl remained higher
than in the rats treated with captopril alone, but there was no significant difference between
the both groups after 11, 19, 27 and 37 weeks of treatment. There was an age-related increase
in daily urinary excretion of albumin after long term treatment, but no significant difference
among different treatment periods in the each group (Figure 16).
Figure 16. Effect of captopril and captopril plus LiCl on daily urinary excretions of albumin in
salt-loaded SHRSP. From 8 weeks of age, SHRSP were treated subcutaneously with vehicle (0.9%
NaCl), LiCl (1.0 mmol/kg/d), captopril (50 mg/kg/d) and captopril plus LiCl lifelong. At different
treatment periods, rats were housed individually in metabolic cages, and urine was collected during a
24 h period for the measurement of albumin concentration.
At 11, 19 and 27 weeks of treatment, daily urinary excretion of albumin in the rats treated
with telmisartan alone or in combination with LiCl remained belowed 40 mg/day. However,
at 37 weeks of treatment, the daily urinary excretion of albumin in both groups significantly
increased compared to the corresponding group at 11, 19 and 27 weeks of treatment (P<0.01).
There was no significant difference between both groups during the 4 different treatment
periods (Figure 17).
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Figure 17. Effect of telmisartan and telmisartan plus LiCl on daily urinary excretions of
albumin in salt-loaded SHRSP. From 8 weeks of age, SHRSP were treated subcutaneously with
vehicle (0.9% NaCl), LiCl (1.0 mmol/kg/d), telmisartan (initially 1.0 mg/kg/d, and finally 0.3
mg/kg/d) and telmisartan plus LiCl lifelong. At different treatment periods, rats were housed
individually in metabolic cages, and urine was collected during a 24 h period for the measurement of
albumin concentration. ∗∗ P<0.01 versus telmisartan-treated animals and ## P<0.01versus telmisartan
plus LiCl-treated animals at 11, 19 and 27 weeks of treatment.
3.1.8 Plasma renin activity
After 21 weeks of treatment, the PRA in captopril and captopril plus LiCl treated rats was
28.4 ± 1.6 or 25.4 ± 2.7 ng Ang I /ml/h, respectively, and there was no significant difference
between the both groups (Table 11).
Table 11. The plasma renin activity in salt-loaded SHRSP at 21 weeks of treatment with
captopril and captopril plus LiCl
______________________________________________________________
Group                      n                     Activity of renin (ng Ang I/ml/h)
______________________________________________________________
Captopril            6                               28.4 ± 1.6
Cap.+Li.                  5                               25.4 ± 2.7
______________________________________________________________
Values are mean ± S.E.M of n rats.
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After 21 weeks of treatment, the PRA in telmisartan and telmisartan plus LiCl treated rats was
22.4 ± 2.7 or 18.0 ± 3.1 ng Ang I /ml/h,  respectively, and there was no significant difference
between both groups (Table 12).
Table 12. The plasma renin activity in salt-loaded SHRSP at 21 weeks of treatment with
telmisartan and telmisartan plus LiCl
______________________________________________________________
Group                      n                     Activity of renin (ng Ang I/ml/h)
______________________________________________________________
Telmisartan          8                              22.4 ± 2.7
Telmi.+ Li.            6                              18.0 ± 3.1
______________________________________________________________
Values are mean ± S.E.M of n rats.
3.1.9 Neurological signs
All animals in the vehicle- and LiCl- groups exhibited at least one of the neurological signs
accompanying stroke: piloerection, jumping,  paralysis of anterior and/or posterior paws,
aggression, prostration, loss of body symmetry and convulsions, a few days before death. Rats
treated with captopril, captopril plus LiCl, telmisartan or telmisartan plus LiCl had slight or
no neurological signs before death.
3.1.10 Histopathologic studies
Five rats from each group were killed after 5 weeks of treatment. All five of the brains
examined from vehicle-treated SHRSP exhibited areas of moderate-to-severe rarefaction,
especially in the cerebral cortex. Other lesions observed in vehicle-treated SHRSP included:
edema, focal infarction, and one rat had hemorrhage. All five of the brains examined from
LiCl-treated SHRSP had the same cerebral lesions as observed in the vehicle group. However,
histological analysis of the all five brains from SHRSP treated with captopril alone or in
combination with LiCl revealed no evidence of cerebrovascular lesions (Figure 18). After a
long term treatment with captopril and captopril plus LiCl, the rats which were very
debilitated or exhibited huge edema a few days before death were killed for histological
analysis. The brains from these rats in both groups showed rarefaction, and one brain from
each group showed infarction and hemorrhage.
Histological analysis of the all five brains from SHRSP treated with telmisartan alone or in
combination with LiCl showed no evidence of cerebrovascular lesions (Figure 18).
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After a long term treatment with telmisartan and telmisartan plus LiCl, the rats which were
very debilitated or exhibited huge edema a few days before death were killed for histological
analysis. The brains from four rats treated with telmisartan showed rarefaction, and only one
from these four brains exhibited hemorrhage and infarction. The brains from six rats treated
with telmisartan plus LiCl showed rarefaction, and only one from these six brains exhibited
hemorrhage and infarction.
3.1.11 TUNEL staining
There were many strong TUNEL labeled cells in the brains from the vehicle treated-rats, and
some TUNEL positive cells distributed in the corresponding areas with infarction (cresyl
violet staining) (Figure 19). LiCl treatment did not significantly change the expression of
TUNEL-positive cells in the brains of salt-loaded SHRSP compared to vehicle. However, rats
treated with captopril alone or in combination with LiCl for five weeks had significantly less
TUNEL positive cells compared to vehicle, in the coronal sections of brains through bregma −
0.3 mm (0.60 ± 0.40 and 0.80 ± 0.58 versus 2.80 ± 0.20, P<0.05), bregma − 3.8 mm (0.60 ±
0.40 and 1.20 ± 0.37 versus 3.00 ± 0.00, P<0.01), and bregma − 5.3 mm (1.00 ± 0.55 and 1.20
± 0.37 versus 3.00 ± 0.45, P<0.05). No significant difference in the amount of TUNEL
positive cells was observed in brain sections through bregma − 1.8 mm. There was no
significant difference on the expression of TUNEL-positive cells between the captopril- and
captopril plus LiCl-groups (Figure 20). Therefore, captopril alone or in combination with LiCl
had anti-apoptotic effect in the brains of salt-loaded SHRSP, but the addition of LiCl to
captopril did not offer further anti-apoptotic effect.
After a long term treatment, only two rats in the captopril group and the captopril plus LiCl
group could be used for TUNEL staining, with no significant difference between the both
groups.
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Figure 18. Cresyl violet staining of brain sections through the brain cortex from salt-loaded SHRSP
treated for 5 weeks with vehicle (A), LiCl (B), captopril (C), captopril plus LiCl (D), telmisartan (E)
and telmisartan plus LiCl (F).
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Figure 19. Cresyl violet staining (A), TUNEL staining (B, C), and double staining with cresyl violet
and TUNEL (D) in the brain of a vehicle-treated salt-loaded SHRSP. Cresyl violet staining shows an
infarct area in the thalamus (A), and with many TUNEL positive strongly labeled cells in the
corresponding area of the adjacent section (B). Cells stained with dark brown color are TUNEL
labeled cells, and cells stained with blue color show surviving cells. Scale bar: A, B, 500 µm; C, 125
µm; D, 50 µm.
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Figure 20. Effect of LiCl, captopril and captopril plus LiCl on apoptotic expression by TUNEL
staining in brains from salt-loaded SHRSP. From 8 weeks of age, SHRSP were treated
subcutaneously with vehicle (0.9% NaCl), LiCl (1.0 mmol/kg/d), captopril (50 mg/kg/d) and captopril
plus LiCl lifelong. After 5 weeks of treatment, 5 rats from each group were killed for TUNEL staining.
∗ P<0.05, ∗∗ P<0.01 versus vehicle-treated animals. Scoring system: 0, no or few TUNEL positive
cells; 1, random TUNEL positive cells; 2, a discrete region of TUNEL positive cells; 3, many strong
TUNEL positive cells; and 4, the entire region is distributed with TUNEL positive cells.
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Salt-loaded SHRSP treated with telmisartan for five weeks had significantly less TUNEL-
positive cells compared to vehicle, in the coronal sections of brains with bregma − 0.3 mm
(0.40 ± 0.40 versus 2.80 ± 0.20, P<0.05) and bregma − 3.8 mm (0.80 ± 0.37 versus 3.00 ±
0.00, P<0.01), but no significant difference in bregma − 1.8 mm and − 5.3 mm. The addition
of LiCl to telmisartan significantly reduced TUNEL-positive cells compared to vehicle, in the
coronal sections of brains with bregma − 3.8 mm (0.20 ± 0.20 versus 3.00 ± 0.00, P<0.01) and
bregma − 5.3 mm (1.00 ± 0.32 versus 3.00 ± 0.45, P<0.05), but not in the section though
bregma − 0.3 mm and bregma − 1.8 mm. There was no significant difference on the
expression of TUNEL-positive cells between the telmisartan- and telmisartan plus LiCl-
groups (Figure 21). Therefore, telmisartan alone or in combination with LiCl had anti-
apoptotic effects in the brains of salt-loaded SHRSP, but the addition of LiCl to telmisartan
did not offer further anti-apoptotic effects.
After a long term treatment, four rats from the telmisartan-group and five rats from the
telmisartan plus LiCl-group were used for TUNEL staining. There was no significant
difference between both groups in the expression of TUNEL-positive cells in the coronal
sections of brains with bregma − 0.3 mm,  − 1.8 mm, − 3.8 mm and − 5.3 mm (Figure 22).
However, after long term treatment, the TUNEL positive cells in the brains of SHRSP in both
groups tended to increase compared to five weeks of treatment, and there were significant
differences between 5 weeks of treatment and a long-term treatment in the telmisartan plus
LiCl-group in bregma − 3.8 mm (0.20 ± 0.20 versus 2.20 ± 0.49, P<0.05) and bregma − 5.3
mm (1.00 ± 0.32 versus 2.80 ± 0.20, P<0.01). The increase in TUNEL-positive cells in the
brains of SHRSP after a long term treatment may be the age –related increase of apoptosis.
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Figure 21. Effect of LiCl, telmisartan and telmisartan plus LiCl on apoptotic expression by
TUNEL staining in brains from salt-loaded SHRSP. From 8 weeks of age, SHRSP were treated
subcutaneously with vehicle (0.9% NaCl), LiCl (1.0 mmol/kg/d), telmisartan (initially 1.0 mg/kg/d,
and finally 0.3 mg/kg/d) and telmisartan plus LiCl lifelong. After 5 weeks of treatment, 5 rats from
each group were killed for TUNEL staining. ∗ P<0.05, ∗∗ P<0.01 versus vehicle-treated animals.
Scoring system: 0, no or few TUNEL positive cells; 1, random TUNEL positive cells; 2, a discrete
region of TUNEL positive cells; 3, many strong TUNEL positive cells; and 4, the entire region is
distributed with TUNEL positive cells.
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Figure 22. Effect of a long-term treatment with telmisartan and telmisartan plus LiCl on
apoptotic expression by TUNEL staining in brains from salt-loaded SHRSP. From 8 weeks of
age, SHRSP were treated subcutaneously with vehicle (0.9% NaCl), LiCl (1.0 mmol/kg/d), telmisartan
(initially 1.0 mg/kg/d, and finally 0.3 mg/kg/d) and telmisartan plus LiCl lifelong. When the rats were
very debilitated they were killed for TUNEL staining. Scoring system: 0, no or few TUNEL positive
cells; 1, random TUNEL positive cells; 2, a discrete region of TUNEL positive cells; 3, many strong
TUNEL positive cells; and 4, the entire region is distributed with TUNEL positive cells.
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3.2 Intraluminal thread model of focal cerebral ischemia
3.2.1 Physiological parameters
3.2.1.1 Mean arterial blood pressure (MAP)
No significant differences in MAP before MCAO, during MCAO and after reperfusion were
apparent between LiCl-treated rats and vehicle-treated rats. However, rats treated with
captopril alone or in combination with LiCl had significantly lower blood pressure levels
during their conscious state and during anesthesia before MCAO, compared to vehicle. Blood
pressure in the both groups was significantly lower during the 90-min MCAO period as well
as the reperfusion period compared to vehicle (Figure 23).
Figure 23. Effect of LiCl, captopril and captoril plus LiCl on mean arterial blood pressure
(MAP) in Wistar rats. After 14 days of treatment with LiCl (1 mmol/kg/d), captopril (25 mg/kg/d)
and captopril plus LiCl, MAP was measured at different time points before, during and after MCAO.
∗ P<0.05, ∗∗ P<0.01 versus vehicle-treated animals.
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Rats treated with telmisartan alone or in combination with LiCl did not significantly change
blood pressure level during their conscious state and during anesthesia before MCAO,
compared to vehicle. However, blood pressure levels in the telmisartan group were
significantly lower at 30, 75 and 90 min after MCAO compared to the vehicle-treated group
(Figure 24). In the telmisartan plus LiCl-treated group blood pressure was significantly lower
at 30, 45, 60, 75, 90 min after MCAO and at 30, 45, 60 min following reperfusion compared
to the vehicle group (Figure 24). The blood pressure levels in telmisartan-, telmisartan plus
LiCl-, LiCl- and vehicle-treated rats were similar in the conscious state following reperfusion
and 24h after reperfusion (Figure 24).
Figure 24. Effect of LiCl, telmisartan and telmisartan plus LiCl on mean arterial blood pressure
(MAP) in Wistar rats. After 14 days of treatment with LiCl (1 mmol/kg/d), telmisartan (0.3 mg/kg/d)
and telmisartan plus LiCl, MAP was measured at different time points before, during and after
MCAO. ∗ P<0.05, ∗∗ P<0.01 versus vehicle-treated animals.
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3.2.1.2 Blood parameters
The values of pH, pCO2, and pO2 in the blood as well as the blood concentrations of
hemoglobin, glucose, lactate and the electrolytes Na+, K+, Ca2+, Cl− were normal in the rats
treated with LiCl, captopril and captopril plus LiCl before ischemia, during ischemia and after
reperfusion, and were not significantly different between the drug-treated groups and the
vehicle-group (Table 13 and 14).
The values of pH, pCO2, and pO2 in the blood as well as the blood concentrations of
hemoglobin, glucose, lactate and the electrolytes Na+, K+, Ca2+, Cl− were normal in the rats
treated with telmisartan before ischemia, during ischemia and after reperfusion, and were not
significantly different from the vehicle group. However, rats treated with telmisartan plus
LiCl had a significantly increased plasma pO2 in the conscious state before MCAO and at 30
and 90 min after MCAO (P<0.01), and a significantly reduced blood concentration of lactate
in the conscious state and during anesthesia just before MCAO (P<0.05), compared to rats
treated with vehicle. (Table 15 and 16).
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Table 13.  Blood parameters before, during and after 90-min MCAO after treatment with
LiCl, captopril and captopril plus LiCl
__________________________________________________________________________________________
                                                                                                        Treatment
        Parameter                                     Vehicle                      LiCl                   Captopril             Captopril+LiCl
                                                              (n=14)                      (n= 7)                    (n= 7)                     (n= 8)
__________________________________________________________________________________________
pH
Conscious before MCAO             7.430 ± 0.006          7.414 ± 0.013         7.426 ± 0.012         7.419 ± 0.010
Anesthesia before MCAO            7.330 ± 0.010          7.301 ± 0.014         7.337 ± 0.008         7.332 ± 0.014
30 minutes after MCAO               7.363 ± 0.018          7.365 ± 0.023         7.362 ± 0.018         7.341 ± 0.013
90 minutes after MCAO               7.404 ± 0.013          7.395 ± 0.025         7.395 ± 0.023         7.368 ± 0.018
30 minutes after Reperfusion        7.361 ± 0.013          7.357 ± 0.015         7.347 ± 0.009         7.324 ± 0.016
pCO2  mmHg
Conscious before MCAO              33.15 ± 1.07            35.59 ± 1.39            33.70 ± 2.65          33.14 ± 1.42
Anesthesia before MCAO              47.37 ± 0.80            50.13 ± 2.76            46.52 ± 0.68          45.73 ± 1.25
30 minutes after MCAO                45.74 ± 1.62            43.39 ± 2.70            40.62 ± 1.51          41.55 ± 1.30
90 minutes after MCAO                38.32 ± 1.11            37.24 ±  2.82           33.95 ± 2.07          35.24 ± 1.10
30 minutes after Reperfusion         41.39 ± 1.13            40.43 ± 2.10            38.65 ± 1.58          37.75 ± 1.58
pO2  mmHg
Conscious before MCAO               79.61 ± 1.67          80.06 ± 1.13            85.53 ± 4.33            82.91 ± 1.26
Anesthesia before MCAO             73.35 ± 1.59          71.17 ± 2.71            77.32 ± 2.42            76.06 ± 2.49
30 minutes after MCAO                75.89 ± 1.86          80.46 ± 3.22            87.12 ± 4.40            81.62 ± 3.16
90 minutes after MCAO               81.29 ± 2.35          83.14 ± 1.88            86.88 ± 2.89            88.40 ± 3.26
30 minutes after Reperfusion        83.54 ± 1.66          84.12 ± 2.43            93.32 ± 3.75            86.61 ± 2.56
cGlu  mg/dL
Conscious before MCAO             112.9 ±  7.3            115.0 ± 5.0             118.3 ± 16.4            112.6 ± 9.0
Anesthesia before MCAO             181.1 ± 6.2             171.4 ± 8.1             181.2 ± 12.2            202.1 ±10.6
30 minutes after                             182.4 ± 9.1             169.6 ± 12.5           172.8 ± 10.9            203.5 ± 17.5
90 minutes after MCAO                181.6 ± 9.4             162.4 ± 14.7           158.8 ± 15.4            165.8 ±12.1
30 minutes after Reperfusion         188.7 ± 10.9           189.8 ± 19.5           178.2 ± 15.7            204.3 ±15.4
cLac  mmol/L
Conscious before MCAO              1.600 ± 0.909         1.543 ± 0.129         1.550 ± 0.165          1.430 ± 0.143
Anesthesia before MCAO             3.357 ± 0.252         3.271 ± 0.344         2.917 ± 0.379          2.520 ± 0.256
30 minutes after MCAO                2.114 ± 0.116         2.171 ± 0.182         2.317 ± 0.316          2.300 ± 0.188
90 minutes after MCAO               2.029 ± 0.116         2.014 ± 0.160         1.800 ± 0.124          2.280 ± 0.255
30 minutes after Reperfusion        1.736 ± 0.107         1.700 ± 0.124         1.500 ± 0.068          2.320 ± 0.474
ctHb  g/dL
Conscious before MCAO             11.65 ± 0.41           12.90 ± 0.58            12.28 ± 0.42            12.06 ± 0.54
Anesthesia before MCAO             14.31 ± 0.32           14.33 ± 0.93            14.37 ± 1.02            14.68 ± 0.31
30 minutes after MCAO                15.15 ± 0.39           15.01 ± 1.02            13.77 ± 1.19            14.02 ± 0.39
90 minutes after MCAO                 15.01 ± 0.33           14.43 ± 0.69            15.20 ± 0.45            14.65 ± 0.52
30 minutes after Reperfusion         14.96 ± 0.35           14.80 ± 0.55            14.48 ± 0.30            13.74 ± 0.59
__________________________________________________________________________________________
Data are mean ± SEM of n rats.
cGlu = plasma concentration of glucose; cLac = plasma concentration of lactate; ctHb = plasma
concentration of hemoglobin.
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Table 14.  Blood electrolytes before, during and after 90-min MCAO after treatment with
LiCl, captopril and captopril plus LiCl
__________________________________________________________________________________________
                                                                                                   Treatment
        Parameter                                   Vehicle                   LiCl                   Captopril          Captopril+LiCl
                                                            (n=14)                  (n= 7)                    (n= 7)                    (n= 8)
__________________________________________________________________________________________
cNa+  mmol/L
Conscious before MCAO              143.2 ± 0.6           140.2 ± 0.6           139.7 ± 0.5           139.0 ± 0.6
Anaesthesia before MCAO           137.7 ± 0.5           135.4 ± 0.8           135.0 ± 0.7           133.9 ± 0.8
30 minutes after MCAO                136.1 ± 0.5           133.9 ± 1.0           133.8 ± 0.7           132.9 ± 0.9
90 minutes after MCAO               135.0 ± 0.7           133.8 ± 1.4           133.2 ± 1.1           132.8 ± 1.0
30 minutes after Reperfusion         134.7 ± 0.5           131.9 ± 0.6           133.3 ± 1.1           132.9 ± 1.2
cK+  mmol/L
Conscious before MCAO              3.576 ± 0.114        3.714 ± 0.208         3.832 ± 0.115        3.451 ± 0.129
Anaesthesia before MCAO           4.588 ± 0.074        4.594 ± 0.236         4.702 ± 0.101        4.305 ± 0.101
30 minutes after MCAO                 4.361 ± 0.115        4.431 ± 0.232         4.967 ± 0.232        4.670 ± 0.168
90 minutes after MCAO                 4.341 ± 0.098        4.361 ± 0.236         4.635 ± 0.172        4.843 ± 0.321
30 minutes after Reperfusion          3.746 ± 0.127        3.955 ± 0.154         4.148 ± 0.168        4.637 ± 0.612
cCa2+  mmol/L
Conscious before MCAO              1.150 ± 0.028         1.191 ± 0.037         1.137 ± 0.031        1.147 ± 0.017
Anaesthesia before MCAO            1.131 ± 0.017         1.127 ± 0.019         1.107 ± 0.015        1.150 ± 0.017
30 minutes after MCAO                1.220 ± 0.014         1.210 ± 0.019         1.138 ± 0.018        1.152 ± 0.015
90 minutes after MCAO                1.175 ± 0.014         1.191 ± 0.029         1.113 ± 0.019        1.194 ± 0.017
30 minutes after Reperfusion         1.184 ± 0.010         1.205 ± 0.024         1.145 ± 0.015        1.182 ± 0.018
cCl−  mmol/L
Conscious before MCAO              112.7 ± 1.3              109.1 ± 1.3            109.8 ± 2.3            109.6 ± 1.5
Anaesthesia before MCAO            106.4 ± 0.6              103.9 ± 1.3            104.0 ± 0.6            104.3 ± 0.7
30 minutes after                             105.5 ± 0.6              103.3 ± 1.2            106.8 ± 1.3            104.0 ± 0.9
90 minutes after MCAO                106.1 ± 0.6              104.4 ± 1.1            106.8 ± 1.2            105.6 ± 0.9
30 minutes after Reperfusion        106.7 ± 0.6              103.8 ± 1.1            106.3 ± 1.2            105.8 ± 0.9
__________________________________________________________________________________________
Data are mean ± SEM of n rats.
cNa+, cK+, cCa2+ and cCl− indicate plasma concentration of Na+, K+, Ca2+ and Cl−.
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Table 15.  Blood parameters before, during and after 90-min MCAO after treatment with
LiCl, telmisartan and telmisartan plus LiCl
__________________________________________________________________________________________
                                                                                                        Treatment
        Parameter                                      Vehicle                      LiCl                 Telmisartan        Telmisartan+LiCl
                                                               (n=14)                     (n= 7)                     (n= 8)                    (n= 7)
__________________________________________________________________________________________
pH
Conscious before MCAO             7.430 ± 0.006          7.414 ± 0.013         7.427 ± 0.016        7.410 ± 0.014
Anaesthesia before MCAO          7.330 ± 0.010          7.301 ± 0.014         7.323 ± 0.014        7.357 ± 0.022
30 minutes after MCAO                 7.363 ± 0.018          7.365 ± 0.023         7.361 ± 0.017        7.409 ± 0.031
90 minutes after MCAO                 7.404 ± 0.013          7.395 ± 0.025         7.372 ± 0.015        7.416 ± 0.028
30 minutes after Reperfusion         7.361 ± 0.013          7.357 ± 0.015         7.325 ± 0.037        7.351 ± 0.020
pCO2  mmHg
Conscious before MCAO              33.15 ± 1.07             35.59 ± 1.39           33.99 ± 0.87         35.20 ± 2.22
Anaesthesia before MCAO            47.37 ± 0.80             50.13 ± 2.76           48.08 ± 1.54         46.08 ± 2.20
30 minutes after MCAO                45.74 ± 1.62             43.39 ± 2.70           42.84 ± 2.11         37.29 ± 3.40
90 minutes after MCAO                38.32 ± 1.11             37.24 ±  2.82          37.61 ± 1.21         32.40 ± 2.70
30 minutes after Reperfusion        41.39 ± 1.13             40.43 ± 2.10           42.24 ± 1.62         38.27 ± 1.31
pO2  mmHg
Conscious before MCAO               79.61 ± 1.67           80.06 ± 1.13          79.68 ± 2.35         92.24 ± 5.77∗∗
Anaesthesia before MCAO             73.35 ± 1.59           71.17 ± 2.71          78.63 ± 2.57         78.75 ± 3.50
30 minutes after MCAO                75.89 ± 1.86           80.46 ± 3.22          84.56 ± 2.70         93.86 ± 3.36∗∗
90 minutes after MCAO                81.29 ± 2.35           83.14 ± 1.88          86.24 ± 3.67        109.00 ± 8.95∗∗
30 minutes after Reperfusion         83.54 ± 1.66           84.12 ± 2.43          85.45 ± 4.27         87.03 ± 3.87
cGlu  mg/dL
Conscious before MCAO               112.9 ±  7.3            115.0 ± 5.0             105.9 ± 2.7            121.3 ± 10.4
Anaesthesia before MCAO           181.1 ± 6.2             171.4 ± 8.1             207.6 ± 21.2          206.3 ± 3.9
30 minutes after                             182.4 ± 9.1             169.6 ± 12.5           172.3 ± 15.9          182.0 ± 16.1
90 minutes after MCAO                181.6 ± 9.4             162.4 ± 14.7           168.0 ± 9.7            170.8 ± 12.8
30 minutes after Reperfusion        188.7 ± 10.9           189.8 ± 19.5           180.7 ± 7.9            194.3 ±11.3
cLac  mmol/L
Conscious before MCAO               1.600 ± 0.909          1.543 ± 0.129        1.613 ± 0.144        1.143 ± 0.113∗
Anaesthesia before MCAO            3.357 ± 0.252          3.271 ± 0.344        3.550 ± 0.408        1.917 ± 0.450∗
30 minutes after MCAO                 2.114 ± 0.116          2.171 ± 0.182        2.171 ± 0.155        2.067 ± 0.421
90 minutes after MCAO                 2.029 ± 0.116          2.014 ± 0.160        2.029 ± 0.087        1.983 ± 0.239
30 minutes after Reperfusion        1.736 ± 0.107          1.700 ± 0.124        1.614 ± 0.067        1.786 ± 0.167
ctHb  g/dL
Conscious before MCAO               11.65 ± 0.41           12.90 ± 0.58           10.99 ± 0.65          12.67 ± 0.97
Anaesthesia before MCAO           14.31 ± 0.32           14.33 ± 0.93           13.73 ± 0.76          14.53 ± 0.44
30 minutes after MCAO                15.15 ± 0.39           15.01 ± 1.02           13.89 ± 0.90          14.46 ± 0.32
90 minutes after MCAO                15.01 ± 0.33           14.43 ± 0.69           13.64 ± 0.93          14.53 ± 0.61
30 minutes after Reperfusion         14.96 ± 0.35           14.80 ± 0.55           13.83 ± 0.66          14.20 ± 0.43
__________________________________________________________________________________________
Data are mean±SEM of n rats.
cGlu = plasma concentration of glucose; cLac = plasma concentration of lactate; ctHb = plasma
concentration of hemoglobin.  ∗ P<0.05,  ∗∗ P<0.01, statistical comparison to the vehicle-pretreated
group.
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Table 16.  Blood electrolytes before, during and after 90-min MCAO after treatment with
LiCl, telmisartan and telmisartan plus LiCl
__________________________________________________________________________
                                                                                                  Treatment
        Parameter                                  Vehicle                   LiCl                 Telmisartan         Telmisartan+LiCl
                                                           (n=14)                   (n= 7)                     (n= 8)                      (n= 7)
__________________________________________________________________________________________
cNa+ mmol/L
Conscious before MCAO          143.2 ± 0.6           140.2 ± 0.6            142.5 ± 0.6            139.2 ± 1.1
Anaesthesia before MCAO          137.7 ± 0.5           135.4 ± 0.8            136.5 ± 0.4            138.7 ± 5.1
30 minutes after MCAO                136.1 ± 0.5           133.9 ± 1.0            134.5 ± 0.7            133.8 ± 1.1
90 minutes after MCAO               135.0 ± 0.7           133.8 ± 1.4            133.6 ± 0.7            132.8 ± 1.7
30 minutes after Reperfusion       134.7 ± 0.5           131.9 ± 0.6            134.2 ± 0.5            134.1 ± 1.1
cK+ mmol/L
Conscious before MCAO             3.576 ± 0.114        3.714 ± 0.208        3.639 ± 0.106        3.693 ± 0.180
Anaesthesia before MCAO           4.588 ± 0.074        4.594 ± 0.236        4.545 ± 0.133        4.667 ± 0.243
30 minutes after MCAO                  4.361 ± 0.115        4.431 ± 0.232        5.099 ± 0.305        4.545 ± 0.103
90 minutes after MCAO                  4.341 ± 0.098        4.361 ± 0.236        4.795 ± 0.472        4.448 ± 0.137
30 minutes after Reperfusion        3.746 ± 0.127        3.955 ± 0.154         4.723 ± 0.733       4.239 ± 0.122
cCa2+ mmol/L
Conscious before MCAO              1.150 ± 0.028          1.191 ± 0.037         1.141 ± 0.016       1.149 ± 0.032
Anaesthesia before MCAO           1.131 ± 0.017          1.127 ± 0.019         1.148 ± 0.023       1.177 ± 0.035
30 minutes after MCAO                1.220 ± 0.014          1.210 ± 0.019         1.214 ± 0.025       1.170 ± 0.018
90 minutes after MCAO                1.175 ± 0.014          1.191 ± 0.029         1.170 ± 0.017       1.185 ± 0.023
30 minutes after Reperfusion        1.184 ± 0.010          1.205 ± 0.024         1.193 ± 0.023       1.209 ± 0.014
cCl− mmol/L
Conscious before MCAO              112.7 ± 1.3             109.1 ± 1.3             111.9 ± 1.0            110.0 ± 2.0
Anaesthesia before MCAO            106.4 ± 0.6             103.9 ± 1.3             104.6 ± 0.8            104.7 ± 1.8
30 minutes after                             105.5 ± 0.6             103.3 ± 1.2             104.8 ± 0.9            105.3 ± 1.5
90 minutes after MCAO                106.1 ± 0.6             104.4 ± 1.1             105.6 ± 0.8            106.7 ± 0.7
30 minutes after Reperfusion         106.7 ± 0.6             103.8 ± 1.1             105.3 ± 0.5            104.9 ± 0.9
__________________________________________________________________________________________
Data are mean±SEM of n rats.
cNa+, cK+, cCa2+ and cCl− indicate plasma concentration of Na+, K+, Ca2+ and Cl−.
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3.2.2 Measurement of regional cerebral blood flow
To reduce the likelihood that any differences in the neurological or histological outcome were
due to alterations in the degree of the ischemic insult, rCBF was monitored before, during and
after ischemia. Rats were only included in the study when MCAO caused an immediate and
constant reduction of the ipsilateral rCBF in the MCA territory by more than 80% during the
90 min of MCAO. Contralateral rCBF fluctuated at ≈100% of baseline in these animals (data
not shown). After filament withdrawal, the ipsilateral rCBF restored to 54-76% of baseline.
Intraischemic rCBF reductions and postischemic reperfusion levels were comparable between
the vehicle- and drug-treated groups, indicating an equivalent relative depth of ischemia
(Figure 25).
Figure 25. Regional cerebral blood flow (rCBF) before, during and after MCAO in vehicle and
drug-treated groups.
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3.2.3 Neurological evaluation
Neurological evaluation was carried out 24 h and 48 h after MCAO by a person who had no
knowledge of the treatment that the rats had received. Two kinds of neurological grading
systems were used, one was the grading scale of 3-18 developed by Garcia et al. (1995),
another one was the grading scale of 0-3 developed by Bederson et al. (1986).
Rats treated with LiCl showed a significantly improved neurological outcome (assessed by
the 3-18 grading scale system) compared to rats treated with vehicle 24 h after MCAO (10.95
± 0.52 versus 9.36 ± 0.30, P<0.05) and 48 h after MCAO (11.60 ± 0.52 versus 9.45 ± 0.51,
P<0.05). A significant difference in the neurological deficit grade between the LiCl- and
vehicle-treated group was also observed 48 h following MCAO using the 0-3 grading scale
system (1.70 ± 0.11 versus 2.27 ± 0.17, P<0.05). Captopril alone or in combination with LiCl
had no beneficial effect on neurological outcome at either time point when compared to
vehicle (Figure 26).
Rats treated with LiCl plus telmisartan showed a significantly improved neurological outcome
(assessed by the 3-18 grading scale system) compared to rats treated with vehicle 24 h after
MCAO (11.23 ± 0.54 versus 9.36 ± 0.30, P<0.05) and 48 h after MCAO (11.73 ± 0.48 versus
9.45 ± 0.51, P<0.01). A significant difference in the neurological deficit grade between the
telmisartan plus LiCl- and the vehicle-treated group was also observed 48 h following MCAO
using the 0-3 grading scale system (1.68 ± 0.14 versus 2.27 ± 0.17, P<0.05). Telmisartan
alone had no effect on neurological outcome at 24 h and 48 h after MCAO when compared to
vehicle-treated rats. However, the addition of LiCl to telmisartan caused a significantly lower
neurological deficit grade compared to rats treated with telmisartan alone 24 h after MCAO
(1.77 ± 0.10 versus 2.35 ± 0.17, P<0.05) as assessed by the 0-3 grading scale system (Figure
27).
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Figure 26. Effect of LiCl, captopril and captopril plus LiCl on neurological outcome in Wistar
rats. Rats were treated with LiCl (1 mmol/kg/d), captopril (25 mg/kg/d) and captopril plus LiCl for 14
days before MCAO, and 2 days after MCAO. 24 h and 48 h after MCAO, neurological outcome were
assessed by the 3-18 grading scale evaluation system (A) and the 0-3 grading scale evaluation system
(B). ∗ P<0.05 versus vehicle-treated animals.
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Figure 27. Effect of LiCl, telmisartan and telmisartan plus LiCl on neurological outcome in
Wistar rats. Rats were treated with LiCl (1 mmol/kg/d), telmisartan (0.3 mg/kg/d) and telmisartan
plus LiCl for 14 days before MCAO, and 2 days after MCAO. 24 h and 48 h after MCAO,
neurological outcome were assessed by the 3-18 grading scale evaluation system (A) and the 0-3
grading scale evaluation system (B). ∗ P<0.05, ∗∗ P<0.01 versus vehicle-treated animals; # P<0.05
versus telmisartan-treated animals.
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3.2.4 Total infarct volume, serial infarct sizes and edema volume
LiCl treatment significantly reduced the total infarct volume by 32.7 % compared to vehicle-
treatment (Table 17, Figure 28 and 29). The rats treated with LiCl  showed significant
reductions in the infarct sizes measured in the cerebrum (+1.3 mm, p<0.01; +0.5 mm, p<0.05;
−0.3 mm, p<0.05 and −1.1 mm, p<0.01 from bregma) compared to rats treated with vehicle
(Figure 29). Edema may influence total infarct volume. Therefore, the  percentage of  the
hemisphere that had undergone a cerebral infarction (%infarct) was calculated using the
equation of Swanson et al. (1990), to correct for cerebral edema. In the LiCl-treated group the
%infarct was significantly less than in the vehicle-treated group (Table 17, Figure 29). LiCl
treatment slightly reduced edema volume when compared to vehicle treatment. However, this
difference did not reach statistical significance (Table 17, Figure 29).
Captopril alone or in combination with LiCl had no effect on total infarct volume, infarct
sizes and edema volume (Table 17, Figure 29).
Table 17.  The effects of LiCl, captopril and captopril plus LiCl on infarct volume and edema
volume in Wistar rats at 48 h after MCAO
__________________________________________________________________
Treatment           n         Infarct Volume              %infarct              Edema Volume
                                             (mm3)                                                      (mm3)
___________________________________________________________________
Vehicle              11         255.4 ± 26.7                32.8 ± 3.4               73.8 ± 11.8
LiCl                   10         171.9 ± 20.8∗              20.8 ± 3.0∗             55.1 ± 8.7
Captopril            9          268.0 ± 17.5                36.0 ± 2.7               71.3 ± 11.2
Cap.+Li.             8          247.7 ± 20.0                31.7 ± 3.0               73.0 ± 10.7
_________________________________________________________________________________
Data are mean ± SEM of n rats. ∗ P<0.05, statistical comparison to the vehicle-treated animals
Telmisartan plus LiCl treatment significantly reduced infarct size in the cerebrum 0.30 mm
posterior to bregma (p<0.05) (Figure 30), but had no effect on total infarct volume compared
to vehicle treatment (Table 18, Figure 30). Edema volume was slightly, but not significantly,
reduced in rats treated with telmisartan plus LiCl when compared to vehicle treatment (Table
18, Figure 30). Telmisartan alone had no effect on either total infarct volume, infarct sizes or
edema volume (Table 18, Figure 30).
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Table 18.  The effects of LiCl, telmisartan and telmisartan plus LiCl on infarct volume and
edema volume in Wistar rats at 48 h after MCAO
________________________________________________________________________
Treatment            n            Infarct Volume             %infarct               Edema Volume
                                                  (mm3)                                                        (mm3)
________________________________________________________________________
Vehicle             11           255.4 ± 26.7                32.8 ± 3.4              73.8 ± 11.8
LiCl                    10           171.9 ± 20.8∗              20.8 ± 3.0∗             55.1 ± 8.7
Telmisartan     10           249.5 ± 16.5                30.2 ± 2.3               81.5 ± 8.6
Telmi.+Li.           11           220.2 ± 13.1                29.6 ± 2.3               53.1 ± 9.4
_________________________________________________________________________________
Data are mean ± SEM of n rats. * P<0.05, statistical comparison to the vehicle-treated animals.
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                              Vehicle                                                                      LiCl
Figure 28. Representative brain slices from a vehicle-treated rat and a LiCl-treated rat 48 h post 90-
min MCAO. The brains were sliced coronally and stained with cresyl violet. The blue area is viable
tissue, and the pale area is the area damaged by the cerebral infarction. Scale bar, 5 mm.
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Figure 29. Effect of LiCl, captopril and captopril plus LiCl on infarct volume (A), percentage of
infarction (B), edema volume (C) and infarct sizes (D). Percentage of infarction (%infarct) was
calculated by the formula of Swanson et al. (1990), and indicate that the damaged volume was
expressed as a percentage of the contralateral hemispheric volume with the correction of edema. Rats
were treated with LiCl (1 mmol/kg/d), captopril (25 mg/kg/d) and captopril plus LiCl for 14 days
before MCAO, and 2 days after MCAO. ∗ P<0.05, ∗∗ P<0.01, versus vehicle-treated animals.
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Figure 30. Effect of LiCl, telmisartan and telmisartan plus LiCl on infarct volume (A),
percentage of infarction (B), edema volume (C) and infarct sizes (D). Percentage of infarction
(%infarct) was calculated by the formula of Swanson et al. (1990), and indicate that the damaged
volume was expressed as a percentage of the contralateral hemispheric volume with the correction of
edema. Rats were treated with LiCl (1 mmol/kg/d), telmisartan (0.3 mg/kg/d) and telmisartan plus
LiCl for 14 days before MCAO, and 2 days after MCAO. ∗ P<0.05, ∗∗ P<0.01, versus vehicle-treated
animals.
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3.2.5 TUNEL staining
TUNEL-positive cells were distributed in the boundary zones (penumbra) and ischemic cores
of the cerebral cortex and caudate putamen of the occluded MCA area. Only densely labeled
cells were considered as positive apoptotic cells, and cells with light diffuse labeling
suggesting necrosis were not counted. We counted the number of TUNEL-positive cells in the
penumbra of the parietal cortex on the section through the anterior commissure (0.3 mm
posterior to the bregma) and on the section 1.8 mm posterior to the bregma. The section
through the anterior commissure revealed significantly less TUNEL-positive cells in rats
treated with LiCl than those treated with vehicle (473 ± 60.7/mm2 versus 805 ± 60.5/mm2,
P<0.01) (Figure 31 and 32).  A 30.3% reduction in the number of TUNEL-positive cells was
obeserved on the section through bregma −1.8 mm, but this difference did not reach statistical
significance.
Captopril alone or in combination with LiCl as well as telmisartan alone or in combination
with LiCl did not decrease the density of TUNEL-positive cells in the cortical penumbra on
either sections (bregma −0.3 mm and −1.8 mm) when compared to vehicle (Figure 32 and
33).
No TUNEL-positive cells were found in the contralateral side.
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Figure 31. TUNEL staining of brain sections from ischemic parietal cortex in a vehicle-treated rat (A,
C) and a LiCl-treated rat (B, D) 48 h after 90-min MCAO. Scale bar: A, B, 250 µm; C, D, 50 µm.
A B
C D
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Figure 32. Effect of LiCl, captopril and captopril plus LiCl on the density of TUNEL positive
cells in the penumbra of parietal cortex in the rats two days after MCAO. Rats were treated with
LiCl (1 mmol/kg/d), captopril (25 mg/kg/d) and captopril plus LiCl for 14 days before MCAO, and 2
days after MCAO. ∗∗ P<0.01 versus vehicle-treated animals.
Figure 33. Effect of LiCl, telmisartan and telmisartan plus LiCl on the density of TUNEL
positive cells in the penumbra of parietal cortex in the rats two days after MCAO. Rats were
treated with LiCl (1 mmol/kg/d), telmisartan (0.3 mg/kg/d) and telmisartan plus LiCl for 14 days
before MCAO, and 2 days after MCAO. ** P<0.01 versus vehicle-treated animals.
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3.2.6 Activated caspase-3 immunoreactivity
The majority of caspase-3 positive cells were distributed in the inner boundary zones
(penumbra) of the cerebral cortex and caudate putamen of the occluded MCA area. On the
other hand, only a few stained cells for caspase-3 were found in the ischemic core region. The
number of caspase-3 positive cells was counted in the penumbra of the parietal cortex on the
section through the anterior commissure (0.3 mm posterior to the bregma) and on the section
1.8 mm posterior to the bregma. Animals treated with LiCl had significantly less caspase-3
positive cells in the penumbral zone on the section through the anterior commissure than
those treated with vehicle (215 ± 35.1 versus 386 ± 45.7, p<0.05) (Figure 34 and 35). On the
section 1.8 mm posterior to the bregma, LiCl treatment reduced the number of caspase-3
positive cells by 32.2 % when compared to vehicle, but this difference did not reach statistical
significance (Figure 35). The number of caspase-3 positive cells was significantly reduced in
brain sections from captopril- and captoptil plus LiCl-treated rats compared to those from
vehicle-treated rats (224 ± 38.9 and 195 ± 25.2 versus 386 ± 45.7 on the section 0.3 mm
posterior to the bregma, p<0.05 and p<0.01; 240 ± 39.5 and 221 ± 25.9 versus 426 ± 45.3 on
the section 1.8 mm posterior to the bregma, p<0.05 and p<0.01). Captopril treatment reduced
the number of caspase-3 positive cells by 42.0 % and 43.7 % , and captopril plus LiCl
treatment reduced the caspase-3 positive cells by 49.5 % and 48.1 % on the sections 0.3 mm
and 1.8 mm posterior to the bregma respectively, compared to vehicle (Figure 34 and 35).
The number of caspase-3 positive cells was reduced in the sections which were 0.3 mm and
1.8 mm posterior to the bregma of brains derived from telmisartan plus LiCl-treated rats (217
± 21.7 versus 386 ± 45.7 in the vehicle-treated group, P<0.01; 253 ± 56.8 versus 426 ± 45.3 in
the vehicle-treated group, P<0.05), and the percent of inhibition was 43.8 and 40.6 on the both
sections respectively, when compared to vehicle (Figure 34 and 36). Telmisartan-treatment
slightly, but not significantly reduced the density of activated caspase-3 positive cells in the
cortical penumbra on the both sections (Figure 34 and 36).
A negligible amount of caspase-3 positive cells were found in the cortical area of the
contralateral side.
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Figure 34. Activated caspase-3 staining on brain sections from ischemic parietal cortex in rats
treated with vehicle (A), LiCl (B), captopril (C), captopril plus LiCl (D), telmisartan (E) and
telmisartan plus LiCl (F) 48 h after 90-min MCAO. Scale bar, 125 µm.
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Figure 35. Effect of LiCl, captopril and captopril plus LiCl on the density of activated caspase-3
positive cells in the penumbra of parietal cortex in the rats two days after MCAO. Rats were
treated with LiCl (1 mmol/kg/d), captopril (25 mg/kg/d) and captopril plus LiCl for 14 days before
MCAO, and 2 days after MCAO. ∗ P<0.05, ∗∗ P<0.01 versus vehicle-treated animals.
Figure 36. Effect of LiCl, telmisartan and telmisartan plus LiCl on the density of activated
caspase-3 positive cells in the penumbra of parietal cortex in the rats two days after MCAO. Rats
were treated with LiCl (1 mmol/kg/d), telmisartan (0.3 mg/kg/d) and telmisartan plus LiCl for 14 days
before MCAO, and 2 days after MCAO. ∗ P<0.05, ∗∗ P<0.01 versus vehicle-treated animals.
B
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3.2.7 Activated Microglia
Inflammatory mediators are involved in the pathogenesis of focal ischemia brain damage. To
determine whether LiCl or inhibitors of the RAS inhibit inflammation, we studied microglial
activation by using the ED1 antibody, a monoclonal antibody specific for reactive microglia
and macrophages.
Activated microglia cells of the amoeboid type (amoeboid microglia), as identified by their
enlarged size and stout processes, were most frequently observed in the boundary zone of the
infarction and to a minor extent in the infarction core at 2 days after MCAO. We counted the
number of activated microglia and macrophages in the penumbra of parietal cortex on the
section through the anterior commissure (0.3 mm posterior to the bregma) and on the section
1.8 mm posterior to the bregma. LiCl treatment only slightly decreased the density of
activated microglia and macrophages on the sections 0.3 mm and 1.8 mm posterior to bregma
(Figure 37 and 38). However, the number of activated microglia and macrophages was
significantly reduced in the brain sections from captopril and captopril plus LiCl-treated rats
compared to those from vehicle-treated animals (339 ± 36.4 and 256 ± 24.6 versus 617 ± 51.8
on the section 0.3 mm posterior to the bregma, p<0.01; 277 ± 21.9 and 307 ± 48.0 versus 541
± 33.6 on the section 1.8 mm posterior to the bregma, p<0.01) (Figure 37 and 38). Captopril
alone or in combination with LiCl reduced the number of activated microglia by 45.1 % and
58.5 % in the section through the anterior commissure, and by 48.8 % and 43.3 % in the
section 1.8 mm posterior to the bregma respectively, compared to vehicle.
The number of activated microglia and macrophages in the penumbra of the brain cortex was
significantly reduced in the telmisartan plus LiCl treated tissues on the section through the
anterior commissure (397 ± 25.3 versus 617 ± 51.8 in the vehicle-treated group, p<0.01)
(Figure 37 and 39). Treatment with telmisartan alone did not significantly decrease the
density of activated microglia and macrophages in the penumbra of cortex on both sections
(Figure 37 and 39).
No activated microglia and macrophages were found on the contralateral side of the brain
sections.
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Figure 37. Activated microglia stained by the ED1 antibody on the brain sections from ischemic
parietal cortex in rats treated with vehicle (A), LiCl (B), captopril (C), captopril plus LiCl (D),
telmisartan (E) and telmisartan plus LiCl (F) 48 h after 90-min MCAO. Scale bar, 125 µm.
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Figure 38. Effect of LiCl, captopril and captopril plus LiCl on the density of activated microglia
in the penumbra of parietal cortex in the rats two days after MCAO. Rats were treated with LiCl
(1 mmol/kg/d), captopril (25 mg/kg/d) and captopril plus LiCl for 14 days before MCAO, and 2 days
after MCAO. ∗∗ P<0.01 versus vehicle-treated animals.
Figure 39. Effect of LiCl, telmisartan and telmisartan plus LiCl on the density of activated
microglia in the penumbra of parietal cortex in the rats two days after MCAO. Rats were treated
with LiCl (1 mmol/kg/d), telmisartan (0.3 mg/kg/d) and telmisartan plus LiCl for 14 days before
MCAO, and 2 days after MCAO. ∗∗ P<0.01 versus vehicle-treated animals.
B
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3.2.8 Li+-concentration in plasma
Plasma Li+-concentration in the drug-treated and vehicle-treated groups is shown in Table 19
and 20. The Li+-concentrations in LiCl-, captopril plus LiCl- and telmisartan plus LiCl-treated
rats remained below the therapeutic concentration range necessary for the treatment of dipolar
disease (0.5-0.9 mmol/L).
Table 19. The concentration of Li+ in the plasma of Wistar rats after
treatment with LiCl, captopril and captopril plus LiCl for 16 days
_________________________________________________________
  Group                                   n                            Li+ (mmol/L)
_________________________________________________________
Vehicle                8                             0.01 ± 0.00
LiCl                     6                             0.40 ± 0.06
Captopril             7                             0.02 ± 0.01
Cap.+Li.              6                             0.37 ± 0.10
_________________________________________________________
                             
Data are mean ± S.E.M of n rats.
Table 20. The concentration of Li+ in the plasma of Wistar rats after
treatment with LiCl, telmisartan and telmisartan plus LiCl for 16 days
_________________________________________________________
  Group                 n                             Li+ (mmol/L)
_________________________________________________________
Vehicle                8                             0.01 ± 0.00
LiCl                     6                             0.40 ± 0.06
Telmisartan         5                             0.02 ± 0.01
Telmi.+Li.           6                             0.29 ± 0.07
_________________________________________________________
Data are mean ± S.E.M of n rats.
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4 Discussion
4.1 Stroke development in salt-loaded SHRSP
SHRSP provide an experimental model of hypertensive cerebrovascular and renal disease.
The occurrence of stroke in these animals is dramatically increased by replacing the drinking
water by a 1% NaCl solution (Nagaoka et al., 1976). In the present study, SHRSP treated with
vehicle developed severe hypertension at 12 weeks of age. Death associated with stroke first
occurred in 12 week old rats with a 100% mortality at 16 weeks of age. Similar mortality rates
in salt-loaded SHRSP have been reported previously (Smeda, 1989). All animals exhibited
neurological signs accompanying stroke and drank dramatically more salt water a few days
before death. A number of histological changes could be observed in brain sections derived
from 13 week old SHRSP including edema, brain cell rarefaction, focal infarctions and
hemorrhages. Furthermore, a high number of apoptotic cells in these brains could be detected
by TUNEL staining, and TUNEL stained apoptotic cells were frequently located to the areas
with focal infarction (cresyl violet staining). To our best knowledge it is the first time to
detect apoptotic cells by TUNEL staining in brains from salt-loaded SHRSP. The mechanisms
by which SHRSP develop stroke rapidly after salt-loading are not quite clear. The present
results suggest a possible contribution of an enhanced apoptosis rate in brains derived from
SHRSP to the pathogenesis of stroke.
Other factors have been postulated to contribute to stroke development in salt-loaded SHRSP.
The participation of the RAS in the development of hypertensive vascular injury has been
widely demonstrated. Numerous studies with ACE inhibitors  and Ang II receptor antagonists
have clearly identified Ang II as a major factor responsible for the development of end-organ
damage in hypertensive vascular disease (Laragh and Sealey, 1990). Physiologically, the RAS
is suppressed by a high salt diet and activated by salt-depletion. However, in SHRSP,
paradoxically, the RAS is, after a transient inhibition, strongly activated in the malignant
phase of hypertension despite salt loading. Morbidity and mortality in salt-loaded SHRSP are
associated with a rise in the activity of the RAS (Volpe et al., 1990; Shibota et al., 1979).
Recently Kyselovic et al. (2001) revealed that the paradoxical plasma renin activity (PRA)
increase in salt-loaded SHRSP is accompanied by elevated renal levels of renin mRNA,
confirming that the physiological downregulation by salt of renin production by the kidney is
lost in those hypertensive rats. Activation of renin production is probably secondary to renal
damage that is accelerated by the high dietary salt intake in this strain, as previously
suggested by others (Matsunaga et al., 1975; Shibota et al.,  1979).
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In the present study, in untreated SHRSP the salt water intake was constant during the first 4
weeks of treatment and tended to increase thereafter. The thirst and salt-appetite-promoting
properties induced by Ang II are responsible for the increase in salt water intake observed
during the days preceding death (Phillips, 1987). Ang II, the most important peptide of the
RAS, exerts a number of actions such as vasoconstriction, renal salt and water retention,
aldosterone and vasopressin release, and sympathetic facilitation, all of which may play a
detrimental role in the hypertensive state (Edling et al. 1995, Griendling et al. 1996).
Additionally, the vascular detrimental influence of the RAS may not be limited to its effects
on vascular resistance and salt and water excretion. Neutrophil adhesion to endothelium is the
first step of leukocyte-mediate vascular injury. An increased adherence of granulocytes to the
luminal surface of aortic and cerebral vascular endothelium and subendothelial space from
SHRSP has been observed. Ang II may influence neutrophil accumulation via production of
neutrophil chemoattractant activity in vascular endothelial cells (Stier et al., 1989). Moreover,
Ang II stimulates the synthesis and release of aldosterone, and it is suggested that the
elevations in plasma aldosterone of salt-loaded SHRSP before stroke may play an important
role in initiation of stroke in SHRSP (Smeda et al., 1999). Recently a growing body of
evidence suggests that the RAS functions as a regulator of apoptosis in a variety of cell types
(Filippatos et al., 2001). The increased apoptosis in the brain of salt-loaded SHRSP may be
associated with the increased activity of RAS.
4.2 Effects of captopril and captopril plus lithium on stroke prevention in
salt-loaded SHRSP
The results of the present study revealed that captopril at a dose of 50 mg/kg per day by a
long-term subcutaneous injection markedly prolonged survival in salt-loaded SHRSP, and
significantly increased average survival days from 39 days in untreated group to 247 days.
The addition of LiCl (1 mmol/kg per day) to captopril (50 mg/kg per day) did not offer further
beneficial effects, and the average survival days in the combination treated group was 225
days. The average survival days in lithium treated group was 36 days, comparable to the
control group. However, our previous results showed that a lower dose of captopril (25 mg/kg
per day)  and LiCl (1 mmol/kg per day) act synergistically to prolong survival in salt-loaded
SHRSP. In this study, the addition of LiCl to captopril increased the average survival from
147 days to more than 237 days, which is similar to the average survival days in rats treated
with captopril at 50 mg/kg per day. Taken together, these results show that the effects of
captopril on survival and stroke prevention in salt-loaded SHRSP were dose dependent,  and
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lithium  acts synergistically with the low dose of captopril (25 mg/kg per day) but not with the
high dose of captorpil (50 mg/kg per day) on survival and stroke prevention in salt-loaded
SHRSP.
In the present study, we detected apoptosis by TUNEL staining in the brains from rats after 5
weeks of treatment, and it is interesting to note that the rats treated with captopril had
significantly less apoptotic events than the rats treated with vehicle. Recently several lines of
evidences showed that captopril may have anti-apoptotic effects. Captopril has been shown to
inhibit Fas-induced apoptosis in human activated peripheral T cells and human lung epithelial
cells, and prevent activation-induced apoptosis in T cell hybridomas by interfering with T cell
activation signals (Odaka  and Mizuochi, 2000). It is suggested that the efficacy of captopril
to inhibit experimental lung fibrogenesis is related to inhibition of apoptosis (Wang et al.,
2000). In our present study, we showed for the first time that captopril had anti-apoptotic
effects in the brain of salt-loaded SHRSP, and this effect may be associated with the
mechanisms by which captopril markedly increased survival and prevent stroke in these rats.
Histological results showed that no cerebrovascular lesions existed in the brains from rats
treated with captopril (50 mg/kg per day) for five weeks. However, five weeks after salt-
loading, all five brains from untreated rats exhibited severe cerebrovascular lesions:
rarefaction, focal infarction and edema, and some areas with rarefaction and infarction in
these brains were corresponding to the areas with strong TUNEL-positive cells. These results
demonstrate that apoptosis is related to stroke occurrence in salt-loaded SHRSP, and the
effect of captopril on stroke prevention in these rats may be partly due to the anti-apoptotic
effect of captopril.
The addition of lithium to captopril (50 mg/kg per day) did not offer further beneficial effects
on survival and stroke prevention in salt-loaded SHRSP. However, in our previous study
lithium and captopril at a low dose (25mg/kg per day) act synergistically on survival in the
same model. The mechanisms involved in this synergistic interactions remain unclear. Many
studies in salt-loaded SHRSP have shown that long-term administration of ACE inhibitors
prevents the development of renal and cerebral damage and reduces mortality in this model
(Stier et al., 1989; Stier et al., 1991; Vacher et al., 1993; Mac Leod et al., 1997). No
information is available on the effects of a combination treatment with lithium and an ACE
inhibitor in this model. Our previous study has shown that the systolic blood pressure in the
rats treated with captopril alone or in combination with lithium remained below control levels
at 12-16 weeks of age. Thereafter, both groups developed severe hypertension, and the blood
pressure in both groups was comparable. These results would suggest that the synergistic
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effects between captopril and lithium on survival and stroke prevention via mechanisms
beyond the reduction of blood pressure.
In contrast, in our present study, the addition of lithium to captopril (50mg/kg perday) further
reduced blood pressure in salt-loaded SHRSP, compared to the rats treated with captopril
(50mg/kg per day) alone. However, despite the more pronounced antihypertensive action of
the combination therapy, there was no further beneficial effect on survival in these rats.
It has been shown that long term lithium treatment protects cultured neurons from different
brain regions against glutamate-induced apoptosis (Nonaka et al., 1998a). Moreover, Chen
and Chuang (1999) reported that long-term, but not acute, lithium treatment protects against
glutamate excitotoxicity by suppressing p53 and Bax expression and increasing Bcl-2
expression in cerebellar granule cells. In addition to the protective effects in vitro, a growing
body of evidence is demonstrating that lithium exert neuroprotective effects in vivo. Inouye et
al. (1995) found that lithium pretreatment delayed radiation-induced apoptosis in the cells of
the external granular layer after newborn mice were exposed to gamma irradiation. In our
present study, 5 weeks of treatment with captopril (50 mg/kg per day) alone or in combination
with lithium significantly reduced the apopototic expression in the brains of salt-loaded
SHRSP when compared with vehicle, but the addition of lithium to captopril did not offer
further anti-apoptotic effect. The reason may be because both treatments completely prevent
salt-loaded SHRSP from stroke. However, we can not rule out the possibility that the
synergistic effects of lithium and captopril at a low dose (25 mg/kg/day) on stroke prevention
in salt-loaded SHRSP in our previous study may be related to their synergistic anti-apoptotic
effect.
In our present study, the plasma lithium concentrations of salt-loaded SHRSP in the captopril
plus lithium group were 0.66 ± 0.01 (n=5) and 0.86 ± 0.21 (n=3) mmol/L at 21 and 39 weeks
of treatment, respectively. Lithium has a narrow therapeutic range, with effective plasma
concentrations ranging from 0.5 to 0.9 mmol/L being close to the toxic concentration of 2.0 to
3.0 mmol/L (Silverstone and Romans, 1996). Therefore,  the average plasma lithium
concentrations in the rats after a long term treatment were in the therapeutic range. However,
the plasma lithium concentration of one rats at 39 weeks of treatment was 1.28 mmol/L,
which is beyond the range of the therapeutic concentrations. It is possible that lithium exerts a
toxic effect on kidney after a long-term treatment. As lithium excretion is achieved almost
exclusively via renal means, its pharmacokinetic fate is highly influenced by age, fluid status
and various haemodynamic factors. Age-related changes in glomerular filtration rates may
result in a prolonged plasma half-life in the elderly population (Finley et al., 1995).
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Interference of the RAS by ACE inhibition may have potentiated lithium toxicity in several
ways. First, it aggravated the hyoptension, which in itself impairs glomerular filtration.
Second, it interfered with the normal autoregulatory response to hypotension, thus worsening
renal failure, and further impairing lithium excretion. Finally, ACE inhibition has also been
associated with varying degrees of renal insufficiency that may reduce lithium clearance rates
(Finley et al., 1995). In our present study, daily urinary albumin excretion remained higher in
rats treated with captopril plus lithium than in rats treated with captopril alone during the
whole treatment period. In contrast, in our previous study, urinary albumin excretion was
lower in captopril (25 mg/kg) plus lithium-treated rats compared to rats treated with captopril
(25 mg/kg per day) alone (Gohlke et al., 1999). These contradictory results may be explained
by toxic interactions between lithium and captopril at a high dose (50 mg/kg per day) on
kidney function, whereas no such adverse interaction may occur between lithium and the low
dose of captopril.
Clinical observations reveal a reduction in lithium clearance in patients stabilized on lithium
after the introduction of an ACE inhibitor, leading to an increase in serum lithium
concentration. This phenomenon can be explained in part by the ACE inhibitor-induced
decrease in aldosterone levels that may lead to sodium depletion and subsequent lithium
retention (Finley et al., 1996). In contrast, in our present study the lithium excretion in the
urine of salt-loaded SHRSP treated with captopril plus lithium tended to gradually increase.
In the present study, salt water intake and urinary sodium excretion was higher in rats treated
with captopril (50 mg/kg per day) plus lithium than  rats treated with captopril alone. The
plasma sodium and potassium concentrations, and the urinary potassium excretion were
comparable between the both groups. Therefore, the fluid and electrolyte status in rats from
both groups seem to remain in balance, which may be one of the reasons why lithium
clearance was not impaired in the present study.
PRA was comparably high (>20 ng Ang I/ml/h) in captopril- and captopril plus lithium
treated rats after 21 weeks of treatment. This finding may be explained by the ACE inhibitor –
induced reduction in circulating Ang II levels, thus impairing the Ang II-mediated feedback
inhibition of renin secretion by the kidney. However, high PRA values are also consistent
with the paradoxical PRA increase in SHRSP after salt-loading.
The body weight in rats treated with captopril alone or in combination with lithium increased
with age, and remained comparable between both groups up to 45 weeks of treatment.
Thereafter, most rats from both groups developed huge edema a few days before death. No
neurological signs or slight neurological signs were seen in rats from both groups a few days
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before their death. Brain hemorrhage was only detectable in one rat from the each treated
group, while all rats showed a marked hypertrophy of their hearts and kidneys. In contrast, as
mentioned above, all rats treated with vehicle or lithium exhibited severe cerebrovascular
lesions and had symptoms of stroke a few days before death. These results suggest that rats
treated with captopril died mainly because of heart and kidney failure as a result of long term
hypertension and salt-loading, but did not develop stroke. Under these conditions, the addition
of lithium does not produce any further beneficial effects but appear to exert nephrotoxic
effects in combination with a high dose of the ACE inhibitor as indicated by an increased
urinary albumin excretion. In contrast, when combined with a low dose of captopril (25
mg/kg per day), lithium prevented the occurrence of stroke in ACE inhibitor treated rats and
further increased survival but did not produce nephrotoxicity after long-term treatment.
In summary, the effects of captopril on survival and stroke prevention in salt-loaded SHRSP
are dose dependent, and the addition of lithium further increased survival when combined
with a low dose of captopril, but not with the higher dose of the ACE inhibitor. The effects of
captopril alone or in combination with lithium on stroke prevention may be associated with
their anti-apoptotic effects.
4.3 Effects of telmisartan and telmisartan plus lithium on stroke prevention
in salt-loaded SHRSP
Our results demonstrated that telmisartan at a dose of 1 mg/kg per day initially and 0.3 mg/kg
per day lifelong by subcutaneous injection markedly prolonged survival in salt-loaded
SHRSP, and significantly increased average survival from 39 days in untreated group to 310
days. Two rats treated with telmisartan survived up to 15 months, which was comparable to
the normal lifespan of SHRSP without salt loading. The addition of lithium to telmisartan did
not offer further beneficial effects, and the average survival in the combination treated-rats
was 317 days. The average survival in lithium treated rats was 36 days, comparable to the
vehicle group. When comparing the survival rate of rats treated with captopril (50 mg/kg/day)
alone or in combination with lithium, treatment with telmisartan alone or in combination with
lithium further increased survival in these rats by 2-3 months.
Telmisartan is a potent, long-lasting, nonpeptide antagonist of the AT1 receptor with very
high lipophilicity (Wienen et al., 2000). It has been shown that, following peripheral
administration, telmisartan can penetrate the blood-brain barrier in a dose- and time-
dependent manner to inhibit centrally mediated effects of Ang II (Gohlke et al., 2001). An
inhibition of centrally mediated effects of Ang II was achieved with doses of 0.3-10 mg/kg
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i.v. and 1-30 mg/kg p.o.. Furthermore, a dose-dependent increase in the CSF concentration of
telmisartan could be measured after one week oral treatment with the AT1 receptor antagonist
(Gohlke et al. 2001). Wagner et al. (1998) revealed that 10 mg /kg of body weight of
telmisartan p.o. reduced blood pressure in SHRSP to a similar extent as 50 mg/kg of body
weight captopril. Therefore, for the purpose of the present study, it was reasonable to start
treatment with telmisartan at a dose of 1 mg/kg per day. However, due to a significant
reduction of blood pressure compared to captopril (50 mg/kg per day) during the first 4 weeks
of treatment, the dose of telmisartan was reduced to 0.3 mg/kg per day. The blood pressure
increased gradually after dose adjustment, but remained below 220 mm Hg. The addition of
lithium to telmisartan did not further reduce blood pressure, and the blood pressure was
comparable between the both groups during the whole treatment period.
We examined histological lesions and detected apoptosis by TUNEL staining in the brains of
salt-loaded SHRSP after 5 weeks of treatment. The results showed that none of the rats treated
with telmisartan alone or in combination with lithium developed stroke. The apoptotic
expression in the brains from the both groups were comparable, all markedly less than in the
vehicle-treated group. It is well established that Ang II may induce apoptosis in various cell
types (Dimmeler et al., 1997; Kajstura et al., 1997; Shenoy et al., 1999; Tanaka et al., 1995).
A recent in vivo study demonstrated that Ang II induces apoptosis in a dose-dependent
manner in proximal tubular cells in adult rats (Cao et al., 2000). It was initially considered
that Ang II induces cell proliferation via the AT1 receptor and influences apoptosis via AT2
receptor (Stoll et al., 1995; Yamada et al., 1996). However, more recent in vitro and in vivo
studies (Leri et al., 1998; Cao et al., 2000) have also suggested that both AT1 and AT2
receptors are involved in both proliferation and apoptosis. Ang II may induce apoptosis via
different receptor signaling pathways, depending on the cell type, the age of the animal, and
local environmental factors (Bonnet et al., 2001). In salt-loaded SHRSP, the RAS is
paradoxically very strongly activated in the malignant phase of hypertension, which is
associated with increased morbidity and mortality due to cerebrovascular and renal lesions in
these rats (Volpe et al., 1990). The results of our present study showed that the AT1 receptor
antagonist telmisartan exhibited anti-apoptotic effects in brains from salt-loaded SHRSP, and
the effects of telmisartan on survival and stroke prevention in these rats may be related to its
anti-apoptotic effect. The addition of lithium to telmisartan did not offer further anti-apoptotic
effects after 5 weeks of treatment, which may be because telmisartan alone at this regimen
completely prevent salt-loaded SHRSP from stroke. After a long term treatment, the amount
of TUNEL positive cells in the brains of SHRSP in both groups tended to increase when
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compared to brains after five weeks of treatment, which may be related to an age-dependent
increase in apoptotic events.
The plasma Li+-concentration in salt-loaded SHRSP treated with telmisartan plus lithium for
21 and 39 weeks were 0.62 ± 0.03 and 0.56 ± 0.02 mmol/L, respectively. They were all in the
therapeutic range, and lithium clearance during different periods of treatment were consistent.
Lithium-induced polydipsia in these rats was observed after 30 weeks of treatment, and
therefore occurred much later than in the rats treated with lithium plus captopril in which the
polydipsia was induced as early as after 8 weeks of treatment. After a long-term treatment
with telmisartan or in combination with lithium, the PRA and urinary albumin excretion were
comparable, and fluid and eletrolytes remained in balance in both groups.
The body weight in both groups were comparable with an age-related increase. However,
after a long-term treatment, most rats in both groups developed huge edema a few days before
death, and these rats showed severe heart and kidney lesions. Comparable to these symptoms,
the daily urinary albumin excretion markedly increased at the late stage in these two groups.
In contrast, the brain lesions from these rats were not severe, only one rat treated with
telmisartan or telmisartan plus lithium showed brain hemorrhages. Moreover, similar to rats
treated with captopril, no neurological signs or slight neurological signs were seen in the rats
from both groups a few days before their death.
In summary, our results demonstrated that telmisartan at initially 1 mg/kg per day and finally
0.3 mg/kg per day by subcutaneous injection markedly prolonged survival in salt-loaded
SHRSP, and the effect of telmisartan on stroke prevention may be associated with its anti-
apoptotic effect. The addition of lithium to telmisartan did not offer further beneficial effect
on survival.
4.4 Effects of lithium on focal cerebral ischemia in normotensive rats
The first important finding of the present study is that chronic treatment with a low dose of
lithium decreased infarct volume and improved neurological outcome. Similar findings were
obtained by  Nonaka and Chuang (1998) in rats with permanent MCAO after chronic
treatment with lithium. In their study, rats were treated with lithium (initially 1.5 mmol/kg,
then 2.3 mmol/kg and finally 3 mmol/kg) for 16 days, and neurological evaluations or
quantification of infarct volume were carried out at 24 h after MCAO. Both studies differ with
respect to the model used (transient versus permanent MCAO), the dose of lithium  (1
mmol/kg versus 3 mmol/kg) and the time point (48 h versus 24 h after MCAO). Furthermore,
in the study by Nonaka & Chuang (1998) no attempt was made to examine the possible
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mechanisms that may be responsible for the lithium-induced neuroprotection. In the present
study, the neuroprotective effects of lithium were associated with a reduction of apoptotic
events in the brain cortex assessed by two different methods. The results clearly demonstrate
that chronic treatment with lithium (1 mmol/kg) inhibites activated caspase-3 expression and
decreases DNA  fragmentation in the brain after transient focal cerebral ischemia. The
apoptotic parameters were evaluated two days after MCAO, since i) pannecrosis is visible 24-
48 h after MCAO (Garcia et al., 1993) and ii) the number of apoptotic cells, mostly neurons,
increases as early as 0.5 h, peaks at 24-48 h and persists for 4 weeks after the onset of
reperfusion. Furthermore, apoptotic cells were located primarily in the inner boundary zone of
the infarct of rats subjected to transient (2 h) focal ischemia. (Li et al., 1995a, b).
Ischemia is known to produce reactive oxygen and nitrogen species, to induce cleavage of
poly(ADP-ribose) polymerase, caspase activation and DNA fragmentation in neuronal cells.
In particular, recent biochemical and immunohistochemical studies have demonstrated
enhanced expression and activation of intracellular proteases, notably caspase-3, which act as
initiators and executants of the apoptotic process (Velier et al., 1999). The involvement of
caspases in apoptotic processes following ischemia is supported by the observation that
treatment with caspase inhibitors reduces ischemia-induced brain damage (Cheng et al., 1998;
Endres et al., 1998). This data suggests that apoptotic mechanisms are activated during
ischemia and that inhibition of apoptosis reduces ischemic brain damage.
The gradual expansion of the ischemic lesion after MCAO has been visualized in the parietal
cortex by microtubule-associated protein 2 immunostaining (Mabuchi et al., 2000). Therefore,
we used the penumbra of the parietal cortex to measure the density of apoptotic and
inflammatory cells to assess the possible therapeutic effects of lithium on apoptotic and
inflammatory processes. Our results demonstrate that lithium significantly inhibited activated
caspase-3 immunoreactivity and decreased DNA fragmentation in the ischemic penumbra of
the brain cortex 48 h after MCAO. Several studies have demonstrated anti-apoptotic effects of
lithium. Chronic treatment with lithium increased the expression of Bcl-2, an anti-apoptotic
protein, both, in vitro and in vivo, and reduced the levels of the pro-apoptotic proteins, p53
and Bax (Manji et al., 1999). This data supports the hypothesis that the lithium-mediated
protection from cerebral ischemia involves anti-apoptotic mechanisms. Cerebral ischemia
induces an exaggerated inflammatory response in the surroundings of  the cerebral infarct that
might contribute to neuronal necrosis and apoptosis due to the release of cytokines and other
neurotoxic factors (Stoll et al., 1998). A significant number of reactive mononuclear
phagocytes, both, microglia and invading macrophages, appears within the infarct area and
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along neighboring marginal areas 2 days after ischemia (Giulian et al., 1993). In the present
study, activated microglia as a parameter for ongoing inflammatory processes, was
investigated 48 h after MCAO. Lithium did not inhibit activated microglia in the ischemic
penumbra of the brain cortex. Therefore, it seems likely that anti-apoptotic, rather than anti-
inflammatory effects of lithium had contributed to its neuroprotective effects.
Numerous studies (Nonaka et al., 1998; Nonaka and Chuang, 1998; Yuan et al., 1999) have
shown that lithium must be chronically administered to reach therapeutic effects.
Furthermore, it has been postulated that lithium may exert major effects at the genomic level.
Recently lithium has been demonstrated to inhibit glycogen synthase kinase-3ß (GSK-3ß), an
enzyme which is involved in proapoptotic-signaling. Therefore, the neuroprotective actions of
lithium may be partly due to inhibition of GSK-3ß (Bijur et al., 2000). Moreover, lithium has
been reported to modulate the activator protein 1 (AP-1) DNA binding activity and the
expression of genes regulated by AP-1. However, the mechanisms underlying these effects
have not been fully elucidated (Yuan et al., 1999).
Our results clearly indicate that the effects of lithium in rats with focal ischemia cannot be
simply explained by indirect effects of the drug on e.g. changes in blood pressure or blood
parameters such as pO2, pCO2, hemoglobin and electrolytes (Na+, K+).
In the present study, the plasma Li+-concentration in Wistar rats after 16 days treatment
reached values of 0.40 ± 0.06 mmol/L. This concentration is below the therapeutic
concentrations of lithium (0.5-0.9 mmol/L) required in man for the treatment of manic
depression (Silverstone and Romans, 1996). In vitro study showed that pre-treatment of
cortical neurons with LiCl suppressed glutamate-induced excitotoxicity at the therapeutic and
sub-therapeutic concentration of 0.2-1.6 mmol/L with almost complete protection at 1
mmol/L (Hashimoto et al., 2002). In the present study, a low dose of lithium reduced the
infarct volume by 32.7%. A more pronounced effect of lithium can be expected at higher
doses as demonstrated by Nonaka & Chuang (1998) who used a 3-fold higher dose of lithium
compared to our study.
In conclusion, we demonstrated that a low-dose treatment with lithium (1 mmol/kg) reduced
infarct volume and improved neurological outcome in rats with transient focal cerebral
ischemia. Lithium showed a significant inhibition of caspase-3 and DNA fragmentation in the
ischemic penumbra of the brain cortex, indicating that a reduction of apoptotic processes is
responsible for the neuroprotective effects of lithium against ischemic brain injury.
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4.5 Effects of captopril and captopril plus lithium on focal cerebral
ischemia in normotensive rats
In the present study, pretreatment of rats with captopril (25 mg/kg/day, sc.) did not exhibit
beneficial effects on infarct volume and neurological outcome following focal brain ischemia.
In contrast, in a previous study, captopril (10 mg/kg) by acute i.v. injection improved
neurological outcome from incomplete cerebral ischemia in rats (Werner C, et al., 1991). The
reason for these discrepancies may be due to differences in the animal model used, the dose
and the duration of captopril administration. In the present study, captopril at a dose of 25
mg/kg by daily subcutaneous injection for 2 weeks significantly decreased blood pressure in
normotensive rats. MAP was reduced in the conscious state and during anesthesia before the
onset of MCAO. Moreover, MAP was consistently lower in the captopril-treated group
compared to the vehicle-treated group during the MCAO and reperfusion period. Therefore, it
can not be excluded that MAP partly remained under the lower limit of the cerebral blood
flow (CBF) autoregulation during the period of  MCAO and reperfusion in rats treated with
captopril. Such an effect would have masked a possible neuroprotective effect of captopril in
the ischemic brain. However, it has been demonstrated that the lower and upper limits of the
CBF autoregulation curve were shifted to lower pressures following treatment with ACE
inhibitors (Barry et al., 1984; Paulson et al., 1985). Therefore brains may be protected against
a decrease of the blood pressure induced by ACE inhibition by a shift of the lower limit of
CBF autoregulation. In the present study, blood pressure in captopril-treated rats remained
below 60 mmHg during 5 to 60 minutes of MCAO, and was about 20 mm Hg lower than the
blood pressure in vehicle-treated rats. Blood pressure was further decreased during the whole
MCAO period by the addition of lithium to captopril. Again, this reduction in blood pressure
may have prevented possible beneficial effects of the combination therapy with captopril and
lithium on infarct volume and neurological outcome. However, the reduction in blood
pressure induced by captopril alone or captopril in combination with lithium did not further
aggravate the ischamic damage compared with vehicle-treated animals.
The results of the present study suggest an anti-apoptotic effect of captopril in the ischemic
brain. Captopril reduced activated caspase-3 immunoreactivity in the ischemic penumbra of
the brain cortex on the sections 0.3 mm and 1.8 mm posterior to the bregma. However, we
were unable to see any significant difference in apoptosis between captopril-treated and
vehicle-treated animals by using the TUNEL technique in the ischemic penumbra of cortex.
One explanation for these discrepancies may be the lack of specificity of the TUNEL
technique in in vivo models, in which both apoptotic and necrotic cells have been shown to be
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labeled with this method (de Torres et al., 1997). An inhibitory effect of captopril on
apoptosis has also been demonstrated in human lung epithelial cells in culture (inhibition of
the Fas-induced apoptosis) and in epithelial cells (inhibition of the bleomycin-induced
apoptosis) (Uhal et al., 1998, Wang et al., 2000).
The addition of lithium to captopril led to more pronounced inhibition of activated caspase-3
positive cells in the ischemic penumbra of brain cortex when compared to captopril alone.
Again, the combination therapy did not decrease the number of TUNEL-positive cells.
Cellular inflammation, triggered by ischemia, is a significant contributor to the final
pathology of ischemic stroke. Microglia is activated after ischemic injury and  can exert
multiple functions by transforming  into phagocytes, or by production of neurotoxic factors
(Banati et al., 1993; Lees, 1993). It has been shown that microglial cells or macrophages both
contribute to the gradual expansion of cerebral infarction through the production of
interleukin-1β (Il-1β) (Mabuchi et al., 2000). Ang II may be involved in pro-inflammatory
processes. Ang II dose-dependently increased the release of interleukin-6 (IL-6) by vascular
smooth muscle cells (VSMC) via stimulation of  AT1 receptors. In the ischemic penumbra of
the brain, the expression of IL-6 appeared at  day 1, increased at  day 3, and remained
elevated up to 14 days after transient (3 hours) MCAO in rats (Block et al., 2000). Ang II has
also been shown to activate nuclear factor kB (NF-kB) and to increase the expression of
monocyte chemoattractant protein-1 (MCP-1) in VSMC and monocytes (Kranzhofer et al.
1999, Hernandez-Presa et al., 1997). NF-kB is a common transcription factor involved in the
regulation of many pro-inflammatory genes (Barnes and Karin, 1997). NF-kB activation is
greatly increased in brain tissue in rodent models of stroke. For example, NF-kB is activated
in CA1 hippocampal neurons of rats following transient global forebrain ischemia. A delayed
increase in NF-kB activation occurred several days after focal ischemia/reperfusion and was
associated with the activation of glial cells (Mattson and Camandola, 2001). Furthermore,
inhibitors of NF-kB exert protective effects against cell damage in certain experimental
paradigms that involve inflammatory responses possibly by the inhibition of the cytokine-
mediated activation of microglial cells (Qin et al., 1998).
In the present study, we detected the density of activated microglia or macrophages in the
ischemic penumbra of the brain cortex, and found that captopril markedly reduced the number
of activated microglia and macrophages. It has been reported that long-term treatment with
captopril exerts an effective anti-inflammatory activity against arthritis in rats. This effect was
mediated via  the reduction of leukotriene B(4) and IL-6 (Agha and Mansour, 2000). ACE
inhibitor treatment attenuated several parameters associated with inflammation that are
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controlled by NF-kB in a rabbit model of atherosclerosis and decreased the activation of NF-
kB in the kidney (Hernandez-Presa et al., 1998, Morrissey and Klahr, 1997). Therefore, a
decrease in Ang II generation by ACE inhibition could account for the reduced activation of
NF-kB. Moreover, it can be speculated that the anti-inflammatory effect of captopril in the
ischemic penumbra of  the brain cortex observed in the present study may be related to its
inhibitory effect on the Ang II-mediated  IL-6 release as well as to the suppression of the Ang
II-mediated activation of NF-kB. However, further studies are necessary to elucidate the anti-
inflammatory effect of ACE inhibitor in the ischemic brain. No additional inhibitory effects
on activated microglia or macrophages were observed  following the addition of lithium to
captopril suggesting that the anti-inflammatory effect was related to the action of captopril.
In the brain, the existence of an active RAS is well documented (Ganten et al., 1984).
Recently Walther et al. (2002) demonstrated a direct correlation between brain angiotensin II
and the severity of ischemic injury in either transgenic mice after focal cerebral ischemia and
in vitro experiments using primary neuronal cultures. Ang II exhibited deleterious effects in
ischemic injury, and neuroprotection against ischemia/hypoxia can be achieved by a drug- as
well as a transgene-induced suppression of AT1 receptor function in vivo and in vitro. It has
been showed that ACE inhibitors decrease ACE in the cerebrospinal fluid (CSF) of rats after
systemic administration, and the ability of the drugs to penetrate from the blood into the CSF
paralleled their lipophilicity (Gohlke et al. 1989). Geppetti et al. (1987) demonstrated a
substantial inhibition of ACE in the human CSF following acute oral treatment of patients
with captopril (75 mg). Moreover, indirect evidence for an inhibition of ACE in CSF after
systemic ACE inhibitor administration stems from in vivo studies demonstrating that the
dipsogenic and pressor effects of i.c.v. injected renin or Ang I were decreased after a single
p.o. dose of captopril (Evered et al., 1980; Unger et al., 1983). Therefore, captopril decreased
Ang II in brain tissue and antagonized the deleterious effect of Ang II in ischemic injury, and
the inhibitory effect of captopril on apoptosis or inflammation in the ischemic penumbra of
brain cortex may be related to its preinhibition of Ang II in the brains of rat before ischemia.
After ischemia, the blood brain barrier was destroyed and more captopril penetrates into brain
tissue to further inhibit ACE and to reduce Ang II production.
In summary, treatment of rats with the ACE inhibitor captopril (25 mg/kg per day s.c.) for 2
weeks before transient focal ischemia and for 2 days postischemia did not improve
neurological deficits and reduce infarction volume. The addition of lithium to captopril did
not provide neuroprotection possibly as a result of excessive blood pressure reduction during
the period of MCAO and reperfusion. However, captopril alone as well as in combination
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with lithium markedly reduced the activity of caspase-3, and decreased the number activated
microglia or macrophages in the ischemic penumbra of the brain cortex. Therefore, captopril
may exert beneficial effects on the delayed neuronal death following brain ischemia.
4.6 Effects of telmisartan and telmisartan plus lithium on focal cerebral
ischemia in normotensive rats
In the present study, telmisartan at a dose of 0.3 mg/kg per day did not improve neurological
deficits and did not decrease infarct volume in normotensive rats with focal ischemia. In a
recent study, it has been demonstrated in normotensive rats that blockade of central AT1
receptors induced by intracerebroventricular infusion of the AT1 receptor antagonist
irbesartan for 5 days prior to the MCAO exerted neuroprotective effects in ischemic neuronal
tissue and improved recovery from brain ischemia (Dai et al., 1999). In addition, the
overexpression of the AP-1 transcription factors, c-Fos and c-Jun, which have been associated
with the induction of apoptosis in neurons and positively correlated with the degree of
neurological deficits following focal brain ischemia, was markedly reduced  by central
pretreatment with the AT1 receptor antagonist. Central AT2 receptors contribute to the
beneficial effects of AT1 receptor antagonists on neurological outcome following cerebral
ischemia (J. Culman, WJ Dai, P. Gohlke, A. Blume, and T. Unger, submitted). However,
systemic (i.v.) treatment with irbesartan (30 mg/kg per day) for 5 consecutive days before
MCAO did not improve neurological deficits. One reason for this lack of effect of
systemically administered irbesartan may be the incomplete and only short-lasting blockade
of brain AT1 receptors (Polidori et al., 1998; Culman et al., 1999; Funk et al., 2000). In
contrast to irbesartan, telmisartan exerts a complete blockade of centrally-mediated effects of
Ang II which – at higher doses – lasted for 24 h. Compared to irbesartan (30-100 mg/kg, i.v.)
much lower doses of telmisartan (0.3-10 mg/kg, i.v.) were necessary to achieve central
effects. However, the dose of subcutaneously applied telmisartan used in the present study
(0.3 mg/kg) may still be not sufficient to adequately block brain AT1 receptors. This would
explain the failure of telmisartan to exhibit beneficial effect in rats with focal cerebral
ischemia.. Therefore, an effective blockade of brain AT1 receptors appears to be crucial for
the neuroprotective effects of AT1 receptor antagonists in ischemic neuronal tissue.
Recently Nishimura et al. (2000) reported that selective antagonism of AT1 receptors by
chronic peripheral administration of the AT1 antagonist candesartan normalized
cerebrovascular autoregulation and protected against brain ischemia in genetically
hypertensive rats. In their study, candesartan at a dose of 0.5 mg/kg per day by subcutaneous
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injection for 2 weeks significantly reduced infarct volume in SHR with focal ischemia. The
reasons for the discrepancies between the both studies may involve (1) the use of different
AT1 antagonists (telmisartan versus candesartan) and (2) the use of normotensive versus
hypertensive rats. Candesartan has a higher affinity to the AT1 receptor when compared to
telmisartan. Furthermore, the blockade of AT1 receptors by candesartan is insurmountable as
a result of its tight binding to and slow dissociation from the receptor. Both drugs also differ
with respect to their ability to penetrate the blood brain barrier. Two recent studies have
compared the ability of both drugs to inhibit centrally mediated effects of Ang II following
peripheral application (Gohlke et al., 2001, Gohlke et al., 2002). The results revealed that
much lower doses of candesartan compared to telmisartan were sufficient to effectively block
central effects of Ang II over a 24 h period despite the fact that telmisartan is the more
lipophilic compound (log D at pH 7.4=+3.2 for telmisartan versus –1.7 for candesartan).
Therefore, candesartan at a dose of 0.5 mg/kg per day appear to be more effective in blocking
brain AT1 receptors when compared to telmisartan (0.3 mg/kg per day). However, in the
present study, the major aim was not to study the effect of an AT1 receptor antagonist on
brain ischemia but to investigate possible synergistic interactions between the AT1 receptor
antagonist and lithium. Therefore, sub-maximal doses of both drugs were included in the
study.
The addition of lithium to telmisartan improved neurological deficits in the rats one day or
two days after MCAO, but did not offer further beneficial effects compared to rats treated
with lithium alone. Lithium treatment significantly decreased infarct volume and reduced
infarct sizes in the sections which were +2.1, +1.3, +0.5, −0.3 and −1.1 mm from bregma.
However, the combination therapy with telmisartan and lithium did not significantly reduce
infarct volume, and only significantly decreased the infarct size in the section with greatest
damage which was 0.3 mm posterior to the bregma. Therefore, it appears that under the
present experimental conditions telmisartan partly abolishes the neuroprotective effects of
lithium. Treatment with telmisartan alone significantly reduced blood pressure at 30, 75 and
90 minutes of MCAO only, while the addition of lithium to telmisartan led to blood pressure
reduction at 30, 45, 60, 75, 90 minutes of MCAO, and 30, 45, 60 minutes following
reperfusion. It has been reported that AT1 receptor antagonists or ACE inhibitors can shift the
upper and lower limits of CBF autoregulation to the left, in the direction of lower blood
pressure, in both normotensive or hypertensive rats (Nishimura et al., 2000; Barry et al., 1984;
Paulson et al., 1985). However, it is not known whether telmisartan at the low dose used in
the present study can exert a similar effect. Therefore, it is possible that the combination
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therapy with telmisartan and lithium abolished the beneficial effect of lithium on infarct
volume because of blood pressure reduction. In contrast, the beneficial effects of the
combination therapy with telmisartan and lithium on neurological outcome still remained.
Although some studies of cerebral ischemia have revealed a close correlation between
histology and behavior (Bederson et al., 1986; Aronowski et al., 1996), other studies have
shown a dissociation between histology and sensorimotor behavior or cognitive function (van
der Staay et al., 1996; Wahl et al., 1992). Several factors could account for the lack of
consistent correlation between histology and behavior. It is possible for the recovery of some
sensorimotor functions to occur spontaneously several days after MCAO in the absence of
accompanying histology improvement (van der Staay et al., 1996). Presumably, these
behavioral improvement are due to compensatory changes that occur elsewhere in the brain.
The most frequently used methods to quantify infarct volume after MCAO are not capable of
measuring diffuse morphological changes, which could affect behavior. Clearly, until there is
a better understanding of how histological changes affect behavior, it will be necessary to
continue assessment of both histological and functional outcomes of potential treatments of
stroke.
It is well established that Ang II induces apoptosis in various cell type via AT1 or AT2
receptor (Bonnet et al., 2001). Therefore, it can be speculated that telmisartan protects
neurons against Ang II which may cause neuronal damage after brain ischemia. In the present
study, treatment with telmisartan at a low dose (0.3 mg/kg) slightly (but not significantly)
reduced activated caspase-3 positive cells in the ischemic penumbra of cortex in the brain
sections which were 0.3 mm and 1.8 mm posterior to the bregma. The addition of lithium to
telmisartan led to a significant decrease in the density of activated caspase-3 positive cells in
the brain sections that were 0.3 mm and 1.8 mm posterior to the bregma, which is consistent
with the anti-apoptotic effect of lithium. Moreover, the combination therapy with lithium and
telmisartan significantly reduced activated microglia or macrophages on sections through the
ischemic penumbra of the brain cortex 0.3 mm posterior to bregma. In contrast, treatment
with telmisartan or lithium alone both failed to significantly inhibit activated microglia in the
ischemic penumbra.
It is interesting to note that the combination therapy with lithium and telmisartan for two
weeks significantly increased pO2 in the plasma of rats before MCAO, and at 30 and 90
minutes of MCAO. Consistent with the increase in the plasma pO2, the plasma concentration
of lactate was significantly reduced before MCAO in the telmisartan plus LiCl-treated group.
Disruption of cerebral energy metabolism is the hallmark of disorders of stroke. Such a
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disruption is due mainly to insufficient supplies of either one or both of the substrates of
aerobic energy metabolism, oxygen and glucose (Schurr and Rigor, 1998).
In summary, telmisartan at a dose of 0.3 mg/kg per day did not exhibit beneficial effects on
neurological deficits and infarct volume in normotensive rats with focal cerebral ischemia.
The combination therapy with telmisartan and lithium improved neurological outcome and
metabolism in the same model, and inhibited both activated caspase-3 and activated microglia
and macrophages in the ischemic penumbra of cortex.
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5. Summary
In the present study, the effect of lithium alone or in combination with the ACE inhibitor,
captopril or the AT1 receptor antagonist, telmisartan, were investigated in two animal models
of stroke: First, the stroke-prone spontaneously hypertensive rat (SHRSP), an animal model of
severe hypertension associated with the development of cerebral, renal and cardiac
dysfunction. In these animals, the onset of stroke is accelerated by salt-loading. Second, a
model of focal cerebral ischemia with 90 min occlusion of the middle cerebral artery
(MCAO) followed by reperfusion.
Stroke-Prone Spontaneously Hypertensive Rats
In a previous study we demonstrated synergistic interactions between captopril (25 mg/kg per
day) and LiCl (1 mmol/kg per day) on survival rate and stroke prevention in salt-loaded
SHRSP. The present study was designed to investigate whether a higher dose of captopril (50
mg/kg per day) could further increase survival in salt-loaded SHRSP and whether the
synergistic effect between lithium and captopril was preserved under these conditions.
Furthermore, we studied the effect of the AT1 receptor antagonist, telmisartan (0.3 mg/kg per
day) alone or in combination with LiCl on the survival rate in these animals.
8 week-old SHRSP were salt-loaded (1% NaCl as drinking solution) and treated
subcutaneously with LiCl alone or in combination with captopril or telmisartan. After 5 weeks
of treatment, brains from 5 rats per group were used for cresyl violet staining (for
determination of infarction volume) and TUNEL staining (for determination of apoptosis).
With the remaining rats drug treatment was continued lifelong. Blood or 24 h urine samples
were collected at different time points. Our results demonstrated that captopril markedly
prolonged average survival time from 39 days in vehicle-treated rats to 247 days. Lithium
alone did not increase survival compared to vehicle (average survival 36 days). The addition
of lithium to captopril caused significant blood pressure reductions compared to captopril
treatment alone, but did not further increase survival (average survival 225 days). Both
treatment regimes completely prevented the occurrence of stroke and significantly reduced
apoptosis 5 weeks after initiation of treatment. The daily urinary excretion of albumin in both
groups increased with age indicating the onset of renal failure. Similar beneficial effects were
also seen after treatment with the AT1 receptor antagonist telmisartan. The average survival
time in telmisartan-treated rats was 310 days. The addition of lithium to telmisartan did not
further increase survival (average survival 317 days). Blood pressure in both groups was
comparable during the whole treatment period.
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Middle Cerebral Artery Occlusion
Normotensive Wistar rats were treated subcutaneously with LiCl (1 mmol/kg per day),
captopril (25 mg/kg per day) and captopril plus LiCl as well as with telmisartan (0.3 mg/kg
per day) and telmisartan plus LiCl. Drug treatment was started 2 weeks before MCAO and
was continued for another 2 days after MCAO. Neurological evaluations were carried out 24
h and 48 h after MCAO. Then, the rats were killed and the brains were used for the
measurement of infarct volume and the immunohistochemical detection of TUNEL, activated
caspase-3 and activated microglia. In separate experiments, blood pressure and other blood
parameters such as pCO2, pO2, electrolytes and blood sugar were measured at different time
points before, during and after MCAO. The results demonstrated that chronic treatment with
lithium decreased the infarct volume and improved the neurological outcome. The
neuroprotective effects of lithium were associated with a reduction of activated caspase-3
expression and inhibition of DNA fragmentation in the ischemic penumbra of the brain
cortex. In contrast, neurological deficits and infarct volume were not affected by captopril
treatment. The addition of lithium to captopril did not provide additional neuroprotection,
possibly due to an excessive blood pressure reduction during the period of MCAO and
reperfusion. However, captopril alone as well as in combination with lithium markedly
reduced the number of cells positively stained for activated caspase-3 and activated microglia
and macrophages in the ischemic penumbra of the brain cortex. Therefore, captopril may
exert beneficial effects on the delayed neuronal death following brain ischemia. Telmisartan
did not exhibit beneficial effects on neurological deficits and infarct volume. The combination
therapy with telmisartan and lithium improved neurological outcome and metabolism and
inhibited both activated caspase-3 and activated microglia or macrophages in the ischemic
penumbra of brain cortex. However, the addition of telmisartan to lithium did not offer further
beneficial effects when compared to lithium alone.
In summary, both inhibitors of the renin-angiotensin system completely prevented the
occurrence of stroke in salt-loaded SHRSP and markedly increased survival in these rats. The
rats survived for about 7-10 months and most of the animals died due to heart and renal
failure. Under these conditions, lithium did not exert further beneficial effects.
In the model of transient focal cerebral ischemia, lithium exhibited neuroprotective effects.
However, there were no synergistic interactions between lithium and captopril or lithium and
telmisartan.
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6. Zusammenfassung
In der vorliegenden Studie wurden die Effekte einer Behandlung mit Lithium alleine oder in
Kombination mit 1. dem ACE Hemmmer Captopril oder 2. dem AT1 Rezeptorantagonisten
Telmisartan in zwei Tiermodellen für den Schlaganfall untersucht: der Schlaganfall-
gefährdeten spontan hypertensiven Ratte (SHRSP), ein Tiermodell der schweren Hypertonie
verbunden mit der Entwicklung zerebraler, renaler und kardialer Dysfunktionen. Bei diesen
Tieren wird das Einsetzen einen Schlaganfalls durch Salzbelastung beschleunigt. Das zweite
Tiermodell war das Setzen einer der fokalen Gehirnischämie mit 90-minütiger Okklusion der
mittleren Zerebralarterie (MCAO) gefolgt von einer Reperfusion bei normotensiven Tieren.
Schlaganfall-gefährdete spontan hypertensive Ratten
In einer früheren Studie konnten wir synergistische Interaktionen zwischen Captopril (25
mg/kg pro Tag) und LiCl (1 mmol/kg pro Tag) hinsichtlich der Überlebensrate und der
Schlaganfallprävention in salzbelasteten SHRSP beobachten. In der vorliegenden Studie sollte
untersucht werden, ob eine höhere Dosis von Captopril (50 mg/kg pro Tag) zu einer weiteren
Steigerung der Überlebensrate führt, und ob der synergistische Effekt zwischen Lithium und
Captopril unter diesen Bedingungen erhalten bleibt. Weiterhin untersuchten wir den Effekt
des AT1 Rezeptorantagonisten, Telmisartan (0.3 mg/kg pro Tag) allein oder in Kombination
mit LiCl auf die Überlebensrate dieser Tiere. Acht Wochen alte SHRSP wurden salzbelastet
(1% NaCl als Trinkflüssigkeit) und subkutan mit LiCl allein oder in Kombination mit
Captopril oder Telmisartan behandelt. Nach 5 Wochen Behandlung wurden die Gehirne von
je 5 Ratten pro Behandlungsgruppe für die Cresylviolett-Färbung (zur Bestimmung des
Infarktvolumens) und die TUNEL-Färbung (zum Nachweis der Apoptose) verwendet. Mit
den verbleibenden Ratten wurde die Behandlung lebenslang fortgesetzt. Blut und 24-Stunden
Urin wurden zu verschiedenen Zeitpunkten gewonnen. Unsere Ergebnisse zeigen, dass
Captopril die mittlere Überlebensrate deutlich von 39 Tagen bei Vehikel-behandelten Ratten
auf 247 Tage verlängerte. Lithium alleine führte zu keiner Verlängerung der Überlebensrate
im Vergleich zu Vehikel (mittlere Überlebensrate 36 Tage).Die Zugabe von Lithium zu
Captopril bewirkte eine signifikante Blutdrucksenkung im Vergleich zur alleinigen Captopril-
Behandlung, führte aber zu keiner weiteren Erhöhung der Überlebensrate (mittlere
Überlebensrate 225 Tage). Beide Behandlungsarten verhinderten vollständig das Auftreten
eines Schlaganfalls und zeigten 5 Wochen nach Beginn der Behandlung eine signifikante
102
Verminderung der Apoptose. Die tägliche Albuminexkretion in den Urin steigerte sich mit
zunehmendem Alter, ein Zeichen für ein einsetzendes Nierenversagen. Vergleichbare
benefizielle Effekte wurde auch nach Behandlung mit Telmisartan beobachtet. Die mittlere
Überlebenszeit bei Telmisartan-behandelten Ratten betrug 310 Tage. Die Zugabe von Lithium
zu Telmisartan führte zu keiner weiteren Erhöhung der Überlebensrate (mittlere
Überlebensrate 317 Tage). Der Blutdruck in beiden Behandlungsgruppen war während des
gesamten Behandlungszeitraumes vergleichbar hoch.
Okklusion der mittleren Zerebralarterie
Normotensive Wistar Ratten wurden subkutan mit LiCl (1 mmol/kg pro Tag), Captopril (25
mg/kg pro Tag) und Captopril plus LiCl sowie mit Telmisartan (0.3 mg/kg pro Tag) und
Telmisartan plus LiCl behandelt. Die Behandlung wurde 2 Wochen vor der MCAO begonnen
und für weitere 2 Tage nach der MCAO fortgeführt. Neurologische Untersuchungen wurden
24h und 48h nach der MCAO durchgeführt. Danach wurden die Tiere getötet und die Gehirne
für die Messung des Infarktvolumens und den immunohistochemischen Nachweis von
TUNEL, aktivierter Caspase-3 und aktivierten Mikroglia verwendet. In getrennten
Experimenten wurde der Blutdruck und weitere Blutparameter wie pCO2, pO2, Elektrolyte
und Blutzucker zu verschiedenen Zeitpunkten vor, während und nach der MCAO gemessen.
Die Ergebnisse zeigten, dass eine chronische Behandlung mit Lithium das Infarktvolumen
senkte und den neurologischen „Outcome“ verbesserte. Die neuroprotektiven Effekte von
Lithium waren begleitet von einer Reduktion der Expression der aktivierten Caspase-3 und
einer Hemmung der DNA Fragmentierung in der ischämischen Penumbra des Gehirncortex.
Im Gegensatz hierzu blieben das neurologische Defizit und das Infarktvolumen nach einer
Behandlung mit Captopril unverändert. Die Zugabe von Lithium zu Captopril brachte keine
zusätzliche Neuroprotektion, möglicherweise aufgrund einer zu starken Blutdrucksenkung
während der Phase der MCAO und der Reperfusion. Eine Behandlung mit Captopril allein
sowie in Kombination mit Lithium verminderte jedoch die Anzahl an Zellen mit positiver
Immunreaktivität für aktivierte Caspase-3 und aktivierte Mikroglia und Makrophagen in der
ischämischen Penumbra des Gehirncortex. Captopril könnte daher vorteilhafte Effekte auf
den verzögerten neuronalen Zelltod nach einer Gehirnischämie haben. Telmisartan zeigte
keine benefiziellen Wirkungen auf das neurologische Defizit und das Infarktvolumen. Die
Kombinationstherapie mit Telmisartan und Lithium verbesserte das neurologische „Outcome“
und den Metabolismus und hemmte sowohl die aktivierte Caspase-3 wie auch die aktivierte
103
Mikroglia und Makrophagen in der ischämischen Penumbra des Gehirncortex. Die Zugabe
von Telmisartan zu Lithium brachte jedoch keine zusätzlichen Vorteile im Vergleich zur
alleinigen Lithiumbehandlung.
Zusammenfassend verhinderten beide Hemmstoffe des Renin-Angiotensin Systems
vollständig das Auftreten eines Schlaganfalls bei salzbelasteten SHRSP und verlängerten
deutlich das Überleben dieser Ratten. Die Ratten überlebten etwa 7 – 10 Monate und der
Großteil der Tiere starb an Herz- und Nierenversagen. Unter diesen Bedingungen erbrachte
eine zusätzliche Behandlung mit Lithium keine weiteren Vorteile. Im Modell der transienten,
fokalen Gehirnischämie war Lithium neuroprotektiv wirksam. Es konnten jedoch keine
synergistischen Interaktionen zwischen Lithium und Captopril oder Lithium und Telmisartan
beobachtet werden.
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